HER2-low abstracts

1000 abstracts

Abstract Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation Congress:ESMO 2024, Search all connections
Abstract A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma Congress:ESMO 2024, Search all connections
Abstract Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study Congress:ESMO 2024, Search all connections
Abstract A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01 Congress:ESMO 2024, Search all connections
Abstract Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation Congress:ESMO 2024, Search all connections
Abstract Association of SARS-COV-2 mRNA vaccines with tumor PD-L1 expression and clinical responses to immune checkpoint blockade Congress:ESMO 2024, Search all connections
Abstract The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/Rα payloads, in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract A phase I, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Comparison of symptom distress ranking between oncology nurses and pediatric patients receiving chemotherapy Congress:ESMO 2024, Search all connections
Abstract The effect of Orem-based oral self-care protocol on high-dose chemotherapy-related oral mucositis and self-care agency in patients for hematologic malignancies: A randomized controlled study Congress:ESMO 2024, Search all connections
Abstract Nursesâ€™ evaluation and education of chemotherapy-induced peripheral neuropathy: A systematic review Congress:ESMO 2024, Search all connections
Abstract Malignant bowel obstruction in advanced cancer: A nurse-led review of symptom management, dietitian involvement and outcomes at two sites of an NHS Hospital Trust Congress:ESMO 2024, Search all connections
Abstract Exercise interventions in the management of chemotherapy-induced peripheral neuropathy Congress:ESMO 2024, Search all connections
Abstract Is my patient constipated? How do I assess? Validity and reliability study of the constipation assessment scale in cancer patients: The case of TÃ¼rkiye Congress:ESMO 2024, Search all connections
Abstract Continuous care unit for patients with cancer: Identification of the user profile and follow-up needs Congress:ESMO 2024, Search all connections
Abstract Scalp cooling in breast cancer: What are women's experiences? A description and qualitative study Congress:ESMO 2024, Search all connections
Abstract Nursing management of cancer treatment related peripheral neuropathy Congress:ESMO 2024, Search all connections
Abstract The health gains of therapeutic touch in cancer patients with pain: A literature review Congress:ESMO 2024, Search all connections
Abstract Impact of a proactive telephone intervention led by the advanced practice nurse aimed at symptom control and toxicity detection on the quality of life of outpatients with lung cancer undergoing treatment Congress:ESMO 2024, Search all connections
Abstract Patient education to support self-management and self-efficacy during immunotherapy: An integrative review Congress:ESMO 2024, Search all connections
Abstract A novel nomogram based on inflammation biomarkers for predicting radiation cystitis in patients with local advanced cervical cancer Congress:ESMO 2024, Search all connections
Abstract Associations between depression and quality of life after hematopoietic stem cell transplantation: A longitudinal study Congress:ESMO 2024, Search all connections
Abstract Quality of life scale-based machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract How to use a theoretical framework to inform intervention development in a breast cancer study? Congress:ESMO 2024, Search all connections
Abstract Why do some patients undergoing laryngectomy for head and neck cancer opt to not reacquire their voice? Congress:ESMO 2024, Search all connections
Abstract Quality-of-Life (QoL) data published by clinical trials supporting drug approvals for renal cell carcinoma (RCC) Congress:ESMO 2024, Search all connections
Abstract â€˜Eating with othersâ€™: Planning, developing and testing a self-management intervention to promote social eating for patients living with and beyond head and neck cancer Congress:ESMO 2024, Search all connections
Abstract A study of sexual dysfunction in Moroccan female survivors of gynaecological cancer: A prospective study about 220 patients Congress:ESMO 2024, Search all connections
Abstract Telehealth interventions and functional outcomes in breast cancer rehabilitation: A systematic review Congress:ESMO 2024, Search all connections
Abstract Exploring the correlation between spiritual health, quality of survival, and meaning of life among breast cancer chemotherapy patients Congress:ESMO 2024, Search all connections
Abstract Quality of life among parents of children with cancer Congress:ESMO 2024, Search all connections
Abstract Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset gastric cancer: A retrospective cohort study on 18877 patients Congress:ESMO 2024, Search all connections
Abstract Canadian resources and strategies to build global oncology nursing excellence Congress:ESMO 2024, Search all connections
Abstract Proposals for implementation of a multidimensional platform for the advancement of oncology nursing in Latin America (The INCREASE proposal) Congress:ESMO 2024, Search all connections
Abstract A nurse-led physical activity educational intervention to improve quality of life in breast cancer women undergoing chemotherapy: A study protocol Congress:ESMO 2024, Search all connections
Abstract Improving physical activity in breast cancer: A nurse-led logical framework project Congress:ESMO 2024, Search all connections
Abstract Evaluation of efficacy of controlled cooling of the extremities for prevention of chemotherapy-induced peripheral neuropathy and conservation of dose intensity: A Dutch, nurse led observational pilot study Congress:ESMO 2024, Search all connections
Abstract Climate change, climate disasters and oncology care: A global survey of oncology nurses Congress:ESMO 2024, Search all connections
Abstract Genetic associations between pan-cancer and phenotype of COVID-19: A bidirectional Bayesian Weighted Mendelian randomization study Congress:ESMO 2024, Search all connections
Abstract Comprehensive pan-cancer exploration of the ubiquitin-proteasome system: A bidirectional Bayesian Weighted Mendelian randomization study Congress:ESMO 2024, Search all connections
Abstract Is breast cancer in men ignored? An awareness study Congress:ESMO 2024, Search all connections
Abstract The RES-project, an on-going intervention aimed at increasing breast cancer screening attendance, among socioeconomically challenged groups Congress:ESMO 2024, Search all connections
Abstract Nutritional risk screening (NRS 2002), Prognostic nutritional index (PNI) and Controlling nutritional status (CONUT) in patients with digestive cancer: An observational study Congress:ESMO 2024, Search all connections
Abstract Exploring the pleasure of eating within children undergoing chemotherapy Congress:ESMO 2024, Search all connections
Abstract Risk of cardiovascular mortality among cancer survivors in the United States: The role of inflammation Congress:ESMO 2024, Search all connections
Abstract Use of pictograms (picto) for outpatients treated for cancer and monitored by telehealth: A feasibility and proof of concept study Congress:ESMO 2024, Search all connections
Abstract Fasting in cancer patients during chemotherapy: A monocentric study Congress:ESMO 2024, Search all connections
Abstract Screening recommendations for and outcomes of male patients (pts) with germline BRCA (gBRCA) Congress:ESMO 2024, Search all connections
Abstract Suicide and digestive cancer: A systematic review Congress:ESMO 2024, Search all connections
Abstract G-8 geriatric screening tool and geriatric nutritional risk index Congress:ESMO 2024, Search all connections
Abstract Barriers and facilitators of optimal engagement with teleoncology for older cancer survivors: A rapid review of qualitative literature Congress:ESMO 2024, Search all connections
Abstract Experience with the routine use of ePROMs in nurse and pharmacist-led telephone clinics for patients with prostate cancer Congress:ESMO 2024, Search all connections
Abstract Development of multidisciplinary DigiCanTrain Digital Competence Framework for cancer care Congress:ESMO 2024, Search all connections
Abstract Descriptive and content analysis of breast cancer vlogs on YouTube Congress:ESMO 2024, Search all connections
Abstract Impact of the free information service My Cancer Navigator according to patients and their relatives: An online survey Congress:ESMO 2024, Search all connections
Abstract Evaluation of acceptance and perceived barriers to mobile health applications among breast cancer patients and caregivers at the National Cancer Institute, Cairo University Congress:ESMO 2024, Search all connections
Abstract Perspectives of patients with prostate cancer on self-management support through mHealth and health-coaching Congress:ESMO 2024, Search all connections
Abstract A multimedia method for pre-test genetic counselling in breast cancer patients: A pilot feasibility study Congress:ESMO 2024, Search all connections
Abstract The challenges of the multidisciplinary work of nurses in the international department at Gustave Roussy Cancer Campus Congress:ESMO 2024, Search all connections
Abstract Stress of conscience in healthcare personnel caring for patients at the end of life during the COVID-19 pandemic Congress:ESMO 2024, Search all connections
Abstract Using the â€˜person-based approachâ€™ to adapt and optimise an eLearning resource to equip professionals to support families when a significant adult with children (>18 years) is at end of life with cancer Congress:ESMO 2024, Search all connections
Abstract Revolutionizing oncological care: Successful implementation of home-based antineoplastic treatments Congress:ESMO 2024, Search all connections
Abstract Clinical characteristics of cancer patients with central venous catheter-related infections: Insights from a single centre study Congress:ESMO 2024, Search all connections
Abstract NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring Congress:ESMO 2024, Search all connections
Abstract A phase I/II study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients (pts) with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) Congress:ESMO 2024, Search all connections
Abstract Stereotactic treatment with neoadjuvant radiotherapy and enfortumab vedotin: A phase I/II study for localized, cisplatin ineligible, muscle invasive bladder cancer (STAR-EV) Congress:ESMO 2024, Search all connections
Abstract INTerpath-005: Phase II study of pembrolizumab (pembro) with V940 (mRNA-4157) versus pembro with placebo (pbo) for adjuvant treatment of resected high-risk muscle-invasive urothelial carcinoma (MIUC) Congress:ESMO 2024, Search all connections
Abstract SOGUG-NEOWIN: A phase II, open-label, multi-centre trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and FGFR gene alterations Congress:ESMO 2024, Search all connections
Abstract Disparities in urothelial carcinoma (UC) drug approval: Contrasting North America and Europe Congress:ESMO 2024, Search all connections
Abstract Nephron-sparing surgery combined with perioperative systemic therapy in select high-risk upper tract urothelial carcinoma (UTUC) Patients: A pilot study for a prospective phase II trial Congress:ESMO 2024, Search all connections
Abstract Intrinsic molecular difference between bladder and upper tract urothelial carcinomas and its impacts in treatment response Congress:ESMO 2024, Search all connections
Abstract Evaluation of event-free survival (EFS) as a surrogate endpoint for overall survival (OS) in muscle-invasive bladder cancer (MIBC) following neoadjuvant (NAD) therapy Congress:ESMO 2024, Search all connections
Abstract Serum nectin-4: Prognostic and predictive value in bladder cancer? Congress:ESMO 2024, Search all connections
Abstract Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA) Congress:ESMO 2024, Search all connections
Abstract First preliminary results of artificial intelligence generated treatment recommendations for urothelial cancer based on multidisciplinary cancer conferences from the KITTU project Congress:ESMO 2024, Search all connections
Abstract Role of first-line immunotherapy in urothelial cancer with bone metastases: A national cancer database analysis of 3971 patients Congress:ESMO 2024, Search all connections
Abstract Neoadjuvant immunotherapy-driven bladder preservation for muscle-invasive bladder cancer: A multicenter, propensity score-matched cohort study Congress:ESMO 2024, Search all connections
Abstract Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study Congress:ESMO 2024, Search all connections
Abstract PUNCH02: Primary results from a phase II study of tislelizumab combined with disitamab vedotin as a bladder preservation therapy for urine tumor DNA (utDNA)-defined clinical complete response (cCR) MIBC patients Congress:ESMO 2024, Search all connections
Abstract Assessing response durability and survival after second-line pembrolizumab in advanced urothelial carcinoma: A multicenter validation of a risk model Congress:ESMO 2024, Search all connections
Abstract Similar genetic profile in early and late-stage urothelial tract cancer suggests that early genomic testing bears the potential of timely personalized treatment in clinical trials Congress:ESMO 2024, Search all connections
Abstract Prognostic factors in metastatic urothelial cancer (mUC): Developing an accessible model for predicting patient survival Congress:ESMO 2024, Search all connections
Abstract Prediction of response and identification of mechanisms of resistance to neoadjuvant chemotherapy according to molecular subtypes in muscle-invasive bladder carcinoma Congress:ESMO 2024, Search all connections
Abstract The combination of high levels of serum cytokeratin fragment 21-1 and VI-RADSâ‰§4 has diagnostic and prognostic value in high-stage bladder cancer Congress:ESMO 2024, Search all connections
Abstract Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression Congress:ESMO 2024, Search all connections
Abstract Efficacy and biomarker analysis of neoadjuvant disitamab vedotin combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study Congress:ESMO 2024, Search all connections
Abstract Epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial cancer in France: A non-interventional database study Congress:ESMO 2024, Search all connections
Abstract Combining whole blood RNA-sequencing (WB-RNA) and circulating tumor DNA (ctDNA) for the early identification of patients (pts) without clinical benefit to immune checkpoint inhibitors (ICI) in metastatic urothelial cancer (mUC) Congress:ESMO 2024, Search all connections
Abstract Expression heterogeneity of ADC-related targets between primary tumors and metastatic lymph nodes in advanced urothelial cancers Congress:ESMO 2024, Search all connections
Abstract Preliminary results from a phase I study of T3011, an oncolytic HSV expressing IL-12 and anti-PD-1 antibody, for BCG-failure non-muscle-invasive bladder cancer (NMIBC). Congress:ESMO 2024, Search all connections
Abstract Novel biomarker, ephrinB2 (B2), predicts resistance to treatment and poor overall survival (OS) metastatic urothelial carcinoma (mUC) Congress:ESMO 2024, Search all connections
Abstract Primary analysis of post-marketing surveillance (PMS) data for avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in Japan Congress:ESMO 2024, Search all connections
Abstract Insights into second-line (2L) systemic treatment (tx) receipt in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany Congress:ESMO 2024, Search all connections
Abstract Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in â‰¥ second line in metastatic urothelial carcinoma (mUC) Congress:ESMO 2024, Search all connections
Abstract A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option Congress:ESMO 2024, Search all connections
Abstract Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC) Congress:ESMO 2024, Search all connections
Abstract Subgroup analyses of patients (pts) with advanced urothelial carcinoma (aUC) who had long-term progression-free survival (PFS) or overall survival (OS) with avelumab first-line maintenance (1LM) in the AVENANCE real-world study Congress:ESMO 2024, Search all connections
Abstract MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study Congress:ESMO 2024, Search all connections
Abstract Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis Congress:ESMO 2024, Search all connections
Abstract Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study Congress:ESMO 2024, Search all connections
Abstract TROP-2 as a promising ADC target in penile squamous cell carcinoma that promotes cell proliferation by activating AKT through PKCÎ± pathway Congress:ESMO 2024, Search all connections
Abstract Prospective evaluation of BCG unresponsive bladder cancer carcinoma in situ identifies genetic mechanisms of immunotherapy resistance and targeted therapy using an ultra-sensitive next generation sequencing minimal residual disease (MRD) assay Congress:ESMO 2024, Search all connections
Abstract Retrospective database analysis of real-world treatment patterns and sequencing in locally advanced or metastatic urothelial carcinoma patients receiving sacituzumab govitecan Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy for muscle-invasive bladder cancer: A multi-center, single-arm, phase II trial Congress:ESMO 2024, Search all connections
Abstract Feasibility and efficacy of split-dose cisplatin with atezolizumab for cisplatin-ineligible urothelial carcinoma (SOGUG-AUREA): Final results Congress:ESMO 2024, Search all connections
Abstract Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC) Congress:ESMO 2024, Search all connections
Abstract Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis Congress:ESMO 2024, Search all connections
Abstract Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial Congress:ESMO 2024, Search all connections
Abstract Disitamab vedotin (DV) plus toripalimab (T) in unresectable locally advanced or metastatic urothelial carcinoma (la/mUC): Long-term outcomes from a phase Ib/II study Congress:ESMO 2024, Search all connections
Abstract Accurate detection of urothelial carcinoma by whole-genome methylation profiling of urinary cell-free DNA Congress:ESMO 2024, Search all connections
Abstract Efficacy of talazoparib and avelumab as a maintenance treatment in patients with advanced/metastatic urothelial carcinoma (mUC) whose disease did not progress after a first-line platinum-based chemotherapy (PBCT): The GETUG-TALASUR trial Congress:ESMO 2024, Search all connections
Abstract Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for â‰¥1 or â‰¥2 years in JAVELIN Bladder 100 Congress:ESMO 2024, Search all connections
Abstract A phase II trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder Congress:ESMO 2024, Search all connections
Abstract Urine-based molecular testing identifies FGFR alteration-positive patients for treatment with TAR-210 Congress:ESMO 2024, Search all connections
Abstract Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE Congress:ESMO 2024, Search all connections
Abstract RUTIVAC-1 study: A randomized, double-blind, placebo-controlled phase I trial to evaluate the immunomodulatory effect of RUTI in individuals with high-risk non-muscle-invasive bladder cancer treated with intravesical BCG Congress:ESMO 2024, Search all connections
Abstract Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma Congress:ESMO 2024, Search all connections
Abstract Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) Congress:ESMO 2024, Search all connections
Abstract Influence of androgen deprivation therapy (ADT) on epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) features in prostate cancer (PCa) Congress:ESMO 2024, Search all connections
Abstract Integrative proteomic profiling in high-grade serous ovarian carcinoma: Unraveling biomarkers and therapeutic targets Congress:ESMO 2024, Search all connections
Abstract Integrative analysis of 26848 human transcriptomes reveals cancer-defining transcriptional architecture at the isoform resolution Congress:ESMO 2024, Search all connections
Abstract Glycan-programmed T cell immunity: Effective adoptive T cell transfer in a CRC preclinical model Congress:ESMO 2024, Search all connections
Abstract 5-methylthioadenosine phosphorylase (MTAP) loss in clinically advanced uveal melanoma (CAUM): A comprehensive genomic profiling (CGP) study Congress:ESMO 2024, Search all connections
Abstract The ATXN3-USP25-TRMT1 axis regulates tRNAm2,2G modification and promotes osimertinib resistance in lung cancer Congress:ESMO 2024, Search all connections
Abstract Multiomic spatial profiling of whole-slide NSCLC tissues from patients receiving anti PD-1 therapy identifies metabolic phenotypes associated with therapy resistance Congress:ESMO 2024, Search all connections
Abstract A multicenter, retrospective study of non-small-cell lung carcinoma (NSCLC) harboring EGFR exon 20 insertions: Distribution, variants, and prevalence of coalterations Congress:ESMO 2024, Search all connections
Abstract Squamous cell carcinoma of unknown primary (SCCUP): A genomic landscape study Congress:ESMO 2024, Search all connections
Abstract Analysis of cytokines, chemokines, and tumor-infiltrating lymphocytes as immunological markers predicting pathological complete response in triple-negative breast cancer: Exploratory analysis of the NACATRINE trial Congress:ESMO 2024, Search all connections
Abstract Organoid establishment from multiple biological sources in biliopancreatic cancers Congress:ESMO 2024, Search all connections
Abstract SLC7A9 suppression increases chemosensitivity by inducing ferroptosis via inhibiting cystine transportation in gastric cancer Congress:ESMO 2024, Search all connections
Abstract Stroma-derived bIgH3 (Î²igH3/TGFBI) is the local mediator of pathological TGFÎ² activity in pancreatic cancer and a target to treat in patients with high fibrotic activity Congress:ESMO 2024, Search all connections
Abstract Super-enhancer driven NR3C1 expression promotes 5-FU resistance in gastric cancer Congress:ESMO 2024, Search all connections
Abstract Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort Congress:ESMO 2024, Search all connections
Abstract Neoadjuvant pembrolizumab in high-risk thyroid cancer (NePenTHe) Congress:ESMO 2024, Search all connections
Abstract Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma and anaplastic thyroid carcinoma: The phase II SETHY, GETNE-T2318 trial design Congress:ESMO 2024, Search all connections
Abstract BrafV600E-induced cancer inflammation in a mouse model of thyroid tumorigenesis Congress:ESMO 2024, Search all connections
Abstract Nomogram for predicting lung metastases in patients with papillary thyroid cancer under 55 years old Congress:ESMO 2024, Search all connections
Abstract Clinical characteristics and prognosis of pediatric patients with papillary thyroid carcinoma Congress:ESMO 2024, Search all connections
Abstract Treatment outcomes of patients with anaplastic thyroid carcinoma (atc): Multicentric data from spanish national registry (regetne-tiroides) Congress:ESMO 2024, Search all connections
Abstract Sequence matters: Impact of first-line response in overall therapeutic outcome in differentiated thyroid cancer. Data from the Spanish national registry of thyroid cancer (REGETNE-Tiroides) Congress:ESMO 2024, Search all connections
Abstract Active surveillance for higher-risk papillary thyroid carcinoma in China: A 10-year retrospective study Congress:ESMO 2024, Search all connections
Abstract Utility of circulating tumoral DNA analysis by multi-gene NGS panels in tracking therapy progression of advanced sporadic medullary thyroid carcinoma Congress:ESMO 2024, Search all connections
Abstract Tyrosine kinase inhibitors-induced erythrocytosis in thyroid cancers: A novel safety signal from a retrospective study Congress:ESMO 2024, Search all connections
Abstract Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC) Congress:ESMO 2024, Search all connections
Abstract Resensitization of BRAF-mutated radioactive iodine refractory differentiated thyroid cancer with longer duration of dabrafenib and trametinib Congress:ESMO 2024, Search all connections
Abstract Dabrafenib and trametinib (D+T) in BRAFV600E differentiated thyroid cancer: A real-world experience in Italy Congress:ESMO 2024, Search all connections
Abstract Camrelizumab plus apatinib mesylate in patients with recurrent or metastatic poorly differentiated thyroid carcinoma (PDTC) /anaplastic thyroid carcinoma (ATC): A prospective, open-label, phase II study Congress:ESMO 2024, Search all connections
Abstract AL2846 in patients (pts) with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) previously treated with tyrosine kinase inhibitors (TKI): Preliminary clinical results from the phase Ib study Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of lenvatinib in patients with chemotherapy-naive advanced or recurrent thymic carcinoma: A multicenter retrospective study Congress:ESMO 2024, Search all connections
Abstract Real-world management and outcome of thymic carcinomas in a tertiary German center Congress:ESMO 2024, Search all connections
Abstract Targeted resequencing designed specifically for thymic epithelial tumours confirmed the high prevalence of GTF2I mutations Congress:ESMO 2024, Search all connections
Abstract Molecular analysis of mesothelioma reveals mutations as prognostic biomarkers for patients treated with the combination of ipilimumab and nivolumab Congress:ESMO 2024, Search all connections
Abstract Multiomics analysis of malignant pleural mesothelioma and the effect of immune checkpoint inhibitors Congress:ESMO 2024, Search all connections
Abstract Clinical actionability of germline alterations in pleural mesothelioma: Results from a multicentric study Congress:ESMO 2024, Search all connections
Abstract Real-world efficacy and toxicity of combination immunotherapy in mesothelioma: North East of England experience Congress:ESMO 2024, Search all connections
Abstract Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma Congress:ESMO 2024, Search all connections
Abstract Methylation subtypes correlate with tumor immune contextures and outcome to ICI therapy of pleural mesothelioma (PM) patients: The NIBIT EPI-MESO study Congress:ESMO 2024, Search all connections
Abstract Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma Congress:ESMO 2024, Search all connections
Abstract Nintedanib(N) as switch maintenance treatment in malignant pleural mesothelioma (MPM) (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG) Congress:ESMO 2024, Search all connections
Abstract Five year results of transbronchial microwave ablation of lung malignancies with electromagnetic navigation guidance Congress:ESMO 2024, Search all connections
Abstract AI-based early prediction of radiation pneumonitis in stage III NSCLC patients Congress:ESMO 2024, Search all connections
Abstract Implementation of remote patient monitoring in thoracic oncology: A real-world experience from 489 pts across 41 centers in France Congress:ESMO 2024, Search all connections
Abstract Home-based physical exercise during neoadjuvant treatment for early breast cancer patients (HoPEx-Breast): A pragmatic randomised controlled trial Congress:ESMO 2024, Search all connections
Abstract Grading the evidence for physical activity and all outcomes in cancer survivors: An umbrella review of more than 700 meta-analytic associations Congress:ESMO 2024, Search all connections
Abstract Deployment of remote patient monitoring in older patients: A real-world experience from 2419 patients across 58 centres in France and Belgium Congress:ESMO 2024, Search all connections
Abstract ESMO-ESTRO consensus recommendations regarding the safety of combining radiotherapy with targeted agents or immunotherapy Congress:ESMO 2024, Search all connections
Abstract Impact of proactive callback in patients with solid tumors receiving systemic therapy: A meta-analysis Congress:ESMO 2024, Search all connections
Abstract Factors and trends associated with alcohol intake in patients with breast cancer Congress:ESMO 2024, Search all connections
Abstract Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective Congress:ESMO 2024, Search all connections
Abstract State of supportive care in oncology 2024: Tumor types, industry support, endpoints, and trial locations Congress:ESMO 2024, Search all connections
Abstract Seasonal impact on subcutaneous port infections among oncological patients Congress:ESMO 2024, Search all connections
Abstract Cannabinoids for cancer-associated symptoms: A systematic review and meta-analysis Congress:ESMO 2024, Search all connections
Abstract Efficacy of virtual reality-based interventions in cancer-related symptom management in AYA's: A systematic review Congress:ESMO 2024, Search all connections
Abstract Time to access to diagnosis and treatment for lung cancer (LC): Experience within an Italian comprehensive cancer center Congress:ESMO 2024, Search all connections
Abstract Importance of prompt medical oncologist (MO) consultation at the Emergency Department (ED): A prospective study in a tertiary hospital on 10,896 admissions in the first quarter of 2024 Congress:ESMO 2024, Search all connections
Abstract Higher modified Glasgow Prognostic Score in cancer patients at the Emergency Department is associated with an increased risk of hospital admissions Congress:ESMO 2024, Search all connections
Abstract Pulmonary function test (PFT) and circulating biomarkers in immune-related pneumonitis (irP) in advanced non-small cell lung cancer (aNSCLC): A real-world multidisciplinary experience Congress:ESMO 2024, Search all connections
Abstract Incidence of myocardial ischemia during treatment with capecitabine: Assessment with Holter recording and cardiac biomarkers Congress:ESMO 2024, Search all connections
Abstract Glucagon-like peptide 1 agonists and anthracycline-associated cardiotoxicity in hematologic malignancies Congress:ESMO 2024, Search all connections
Abstract The effects of glucagon-like peptide 1 agonists on immune checkpoint inhibitor-associated cardiotoxicity Congress:ESMO 2024, Search all connections
Abstract End-of-Life (EOL) systemic anticancer treatment (SACT) and health services use before and during the COVID-19 pandemic Congress:ESMO 2024, Search all connections
Abstract Addressing unmet needs in the management of persistent severe cancer pain: European expert recommendations Congress:ESMO 2024, Search all connections
Abstract PalliScore: Validation of a rapid scoring system for enhancing decision-making in the Emergency Department for cancer patients in palliative care Congress:ESMO 2024, Search all connections
Abstract Effect of logotherapy on chronic sorrow, dignity, and meaning in life of palliative care patients Congress:ESMO 2024, Search all connections
Abstract Expectations and priorities of older patients with cancer: The PRIORITY multicenter cohort study Congress:ESMO 2024, Search all connections
Abstract Serum ATG5 protein may determine chemotherapy-related cognitive dysfunction in older patients with cancer Congress:ESMO 2024, Search all connections
Abstract Development and validation of a prediction tool for severe treatment-related toxicities in older cancer patients on systemic treatment (TR-TRM) Congress:ESMO 2024, Search all connections
Abstract Impact of geriatrician-implemented Interventions on chemotherapy (CT) delivery in vulnerable elderly patients with early or advanced solid tumors: The GIVE trial Congress:ESMO 2024, Search all connections
Abstract Awareness of chemotherapy induced nausea and vomiting and adherence to guidelines: A multinational and multicenter survey Congress:ESMO 2024, Search all connections
Abstract Enhancing chemotherapy-induced nausea and vomiting management: Insights into guideline adherence and patient outcomes Congress:ESMO 2024, Search all connections
Abstract Antiemetic prophylaxis during chemoradiation: Sub-study of the GAND-emesis trial identifying dosimetric predictors for vomiting Congress:ESMO 2024, Search all connections
Abstract Effectiveness of intravenous fosnetupitant & palonosetron for cinv prophylaxis in patients receiving highly emetogenic chemotherapy regimens: Subgroup analysis from a phase IV Indian study Congress:ESMO 2024, Search all connections
Abstract Efficacy of surgical gloves (SG) as compression therapy to prevent oxaliplatin-induced peripheral neuropathy (PN): The ELEGANT trial Congress:ESMO 2024, Search all connections
Abstract Adverse effects (AEs) of trastuzumab deruxtecan (T-DXd) in solid tumours: A meta-analysis Congress:ESMO 2024, Search all connections
Abstract Real-world evidence of ribociclib induced liver toxicity in patients with breast cancer: A multi-center experience Congress:ESMO 2024, Search all connections
Abstract Time to vomiting after chemotherapy in association with number of emetic risk factors among breast cancer patients receiving highly emetogenic chemotherapy Congress:ESMO 2024, Search all connections
Abstract Thalidomide for the treatment of chemotherapy-induced night sweats in patients with pancreatic cancer Congress:ESMO 2024, Search all connections
Abstract Evaluation of PROMISE, grim, and cti scores for predicting 90-day mortality in hospitalized cancer patients: A retrospective analysis at a single center Congress:ESMO 2024, Search all connections
Abstract Temperature-controlled hand-foot cooling combined with compression prevents chemotherapy-induced polyneuropathy (CIPN): A single center, prospective, real-world data collection Congress:ESMO 2024, Search all connections
Abstract Safety and efficacy of cryotherapy in the prevention and treatment of chemotherapy-induced peripheral neuropathy Congress:ESMO 2024, Search all connections
Abstract Risk factors for reduced relative dose intensity (RDI) in patients with solid tumors receiving chemotherapy (CT) and primary prolonged G-CSF prophylaxis by empegfilgrastim: Analysis of DEFENDOR study Congress:ESMO 2024, Search all connections
Abstract Development and validation of a clinical prediction model for paclitaxel hypersensitivity reaction: Pac-HSR score Congress:ESMO 2024, Search all connections
Abstract Efficacy of lower dose of dexamethasone premedication in patient receiving docetaxel-based chemotherapy in preventing hypersensitivity reaction: A randomized controlled trial Congress:ESMO 2024, Search all connections
Abstract Metabolic and quality of life changes with the use of dexamethasone pre-paclitaxel in patients with breast cancer Congress:ESMO 2024, Search all connections
Abstract DEFENDOR special: Real-world use of pegylated granulocyte-colony stimulating factor in patients with gastrointestinal cancers Congress:ESMO 2024, Search all connections
Abstract Study on the real-life use of G-CSF in patients with lung cancer: Secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG Congress:ESMO 2024, Search all connections
Abstract Circulating biomarkers for risk stratification of cancer patients with chemotherapy associated febrile neutropenia Congress:ESMO 2024, Search all connections
Abstract A single-arm, phase II trial of hetrombopag for the treatment of concurrent chemoradiotherapy-induced thrombocytopenia in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Poly (ADP-Ribose) polymerase inhibitors (PARPI): Associated thrombosis in patients with ovarian cancer Congress:ESMO 2024, Search all connections
Abstract The impact of sodium-glucose cotransporter-2 inhibitors on thrombosis and cardiovascular disease in patients with polycythemia vera or essential thrombocytopenia Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of thromboprophylaxis in oncology patients with Khorana score<2: Combined results from GMaT and ACT4CAT studies Congress:ESMO 2024, Search all connections
Abstract Machine learning models (MLM) predict venous thromboembolism events (VTE) in Asian oncological inpatients better than the Khorana Score (KS) Congress:ESMO 2024, Search all connections
Abstract Prediction of clinically significant bleeding in anticoagulated patients for cancer-associated venous thromboembolism: Validation of B-CAT score in a cohort from the TESEO study Congress:ESMO 2024, Search all connections
Abstract Analyzing the utility of the cancer therapy satisfaction questionnaire (CTSQ) Congress:ESMO 2024, Search all connections
Abstract Assessing mortality rates within 30 days following the last dose of immunotherapy: A multi-center retrospective study Congress:ESMO 2024, Search all connections
Abstract Risk model for overall survival (OS) based on composite patient-reported outcomes (PROs) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy Congress:ESMO 2024, Search all connections
Abstract The use of patient-reported outcome measures to assess toxicities and quality of life associated with immune checkpoint inhibitor therapy: A systematic review Congress:ESMO 2024, Search all connections
Abstract Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: A systematic review and meta-analysis Congress:ESMO 2024, Search all connections
Abstract Management and potential factors of immunotoxicity in patients with metastatic non-small cell lung cancer receiving first-line treatment with immune checkpoint inhibitors Congress:ESMO 2024, Search all connections
Abstract Clinical predictors of long-term responses to immune checkpoint inhibitors (ICI) in a multi-tumor cohort Congress:ESMO 2024, Search all connections
Abstract Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: Multicentre experience Congress:ESMO 2024, Search all connections
Abstract Safety and efficacy of immune checkpoint inhibitors in patients over 85 years: ICIPO85 study Congress:ESMO 2024, Search all connections
Abstract Social determinants of health in studies assessing toxicities associated with immune checkpoint inhibitor treatment: A systematic review Congress:ESMO 2024, Search all connections
Abstract The impact of body mass index (BMI) on immune-related adverse events (irAEs) and acute care use among patients receiving immune checkpoint inhibitors (ICIs): A population-based study Congress:ESMO 2024, Search all connections
Abstract 3-year experience of the Belgian multidisciplinary immunotoxicity board (BITOX): A nationwide initiative of the Belgian Society of Medical Oncology (BSMO) Congress:ESMO 2024, Search all connections
Abstract Safety of immunotherapy in cancer patients with comorbidities: Results of the phase IV Italian immuno-special trial Congress:ESMO 2024, Search all connections
Abstract The experience of women with breast or gynecological cancer after participation in the online mindfulness-based cancer recovery program (eMBCR) Congress:ESMO 2024, Search all connections
Abstract Feasibility of wrist-worn health-tracker data to predict the need for therapy modifications in patients with metastatic cancer Congress:ESMO 2024, Search all connections
Abstract Ready for digital health? A national mirror survey exploring the perspectives of both patients and healthcare professionals Congress:ESMO 2024, Search all connections
Abstract Dynamic reporting of treatment related symptoms via ePROs can reversely identify the type of underlying cancer Congress:ESMO 2024, Search all connections
Abstract AI-based smart oncology follow-up system: Prospective application testing and enhancement of clinical efficacy. Congress:ESMO 2024, Search all connections
Abstract Assessing care complexity in remote patient monitoring (RPM): A cohort study of 2434 cancer patients across 50 sites in France and Belgium Congress:ESMO 2024, Search all connections
Abstract Patient-reported health behaviors (PRHB) among 1850 patients enrolled in a remote patient monitoring (RPM) pathway Congress:ESMO 2024, Search all connections
Abstract Multi-centre, randomised controlled trial of digital health cancer solution for cancer patients receiving chemotherapy Congress:ESMO 2024, Search all connections
Abstract Accuracy of recommendations by a conversational Artificial Intelligence (AI) cancer mentor application (app): A multi-disciplinary, multi-institutional evaluation report Congress:ESMO 2024, Search all connections
Abstract JUMP_START: Optimization of multiprofessional care for young patients with colorectal cancer Congress:ESMO 2024, Search all connections
Abstract Physical condition is associated with quality of life in colorectal cancer survivors: Results from a Portuguese and Spanish cohort of patients Congress:ESMO 2024, Search all connections
Abstract Obesity and weight variations before treatment, seem to influence weight loss that happens during first-line metastatic lung adenocarcinoma Congress:ESMO 2024, Search all connections
Abstract Comprehensive prognostic effects of inflammatory and nutritional markers to predict survival in women with breast cancer Congress:ESMO 2024, Search all connections
Abstract Nutritional status assessment for patients with common cancer in a cancer hospital of southwest China Congress:ESMO 2024, Search all connections
Abstract A cross-sectional study investigating the current diagnostic & therapeutical approaches to bone metastases (BoM) in patients (pts) with non-small cell lung cancer (NSCLC) Congress:ESMO 2024, Search all connections
Abstract Bone health and body composition in prostate cancer: An italian consensus about prevention and management strategies Congress:ESMO 2024, Search all connections
Abstract Risk factors and incidence of osteoporosis in patients with breast cancer according to gender Congress:ESMO 2024, Search all connections
Abstract Sarcopenia in advanced non-small cell lung cancer (NSCLC): Clinical impact and its biological correlates Congress:ESMO 2024, Search all connections
Abstract Significance of skeletal muscle measurement in cancer-associated cachexia screening Congress:ESMO 2024, Search all connections
Abstract Incidence of cachexia and health resource use (HRU) in patients with breast, colorectal, lung, pancreatic, and prostate cancers Congress:ESMO 2024, Search all connections
Abstract Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin (CP) and etoposide (ETOP) in patients (pts) with small cell lung cancer (SCLC) that progressed after platinum-based therapy: A phase I dose escalation and expansion study Congress:ESMO 2024, Search all connections
Abstract IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC) Congress:ESMO 2024, Search all connections
Abstract SKYBRIDGE study: An open-label, multicenter, dose escalation and dose expansion phase I/II study of PT217 as a monotherapy and in combination with an atezolizumab, in patients with SCLC, LCNEC and EP-NEC known to express DLL3 Congress:ESMO 2024, Search all connections
Abstract MYC expression defines distinct transcriptomic landscape and affects response to DNA-damaging therapies in SCLC Congress:ESMO 2024, Search all connections
Abstract Validation of the lung inmune prognostic (LIPI) index in first-line immunotherapy treatment of small cell lung carcinoma Congress:ESMO 2024, Search all connections
Abstract Immunotherapy retreatment with serplulimab versus chemotherapy in extensive-stage advanced small cell lung cancer previously treated with first-line immunotherapy: A real-world retrospective cohort study Congress:ESMO 2024, Search all connections
Abstract Spatial analyses revealed MMP7 as the biomarker of tumor boundary correlated with immune resistance in small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract Clinical characteristics and management of small cell lung cancer long survivors Congress:ESMO 2024, Search all connections
Abstract PKD1L1 mutations in small cell lung cancer: A genomic signature for poor prognosis and drug susceptibility Congress:ESMO 2024, Search all connections
Abstract Atezolizumab plus chemotherapy followed by atezolizumab plus anlotinib in the first-line treatment for extensive-stage small cell lung cancer: A multicenter, single-arm, prospective real-world study Congress:ESMO 2024, Search all connections
Abstract Analysis of samples from the SCLC REACTION trial: Discovery of biomarkers to optimize treatment Congress:ESMO 2024, Search all connections
Abstract Cost-effectiveness study of atezolizumab (ATZ) vs. durvalumab (DUR) in elderly extensive disease small cell lung cancer (ED-SCLC) patients (pts): Real-world data (RWD) on first-line chemotherapy combined with immune-checkpoint inhibitors (Chemo-ICIs) Congress:ESMO 2024, Search all connections
Abstract Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide Congress:ESMO 2024, Search all connections
Abstract Breaking chemo-immunotherapy resistance in SCLC-patient derived tumor with novel DDRi combinations Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of integrating consolidative thoracic radiotherapy with immunochemotherapy in ES-SCLC: A real-world retrospective analysis Congress:ESMO 2024, Search all connections
Abstract Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE) Congress:ESMO 2024, Search all connections
Abstract Association between baseline PD-L1 expression in circulating leukocytes, the presence of immune-related adverse events (irAEs) and survival outcomes in patients with extensive-stage small-cell lung cancer (ES-SCLC) from the CANTABRICO trial Congress:ESMO 2024, Search all connections
Abstract Smoking-related genomic mutation patterns in patients with small cell lung cancer treated in ASTRUM-005 study Congress:ESMO 2024, Search all connections
Abstract Consolidation serplulimab following concurrent hypofractionated chemoradiotherapy for limited-stage SCLC: Preliminary analysis of phase II ASTRUM-LC01 study Congress:ESMO 2024, Search all connections
Abstract Deciphering ERBB2-driven mechanisms that regulate tumor immune evasion and metastasis in SCLC Congress:ESMO 2024, Search all connections
Abstract Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the Canadian small cell lung cancer database (CASCADE) Congress:ESMO 2024, Search all connections
Abstract Molecular characterization from IMfirst: Atezolizumab plus chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) in Spain Congress:ESMO 2024, Search all connections
Abstract Thoracic radiotherapy plus maintenance durvalumab after first-line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ED-SCLC): A multicenter single-arm open-label phase II trial (SAKK 15/19)tle Congress:ESMO 2024, Search all connections
Abstract Phase II data of lurbinectedin (LUR) and irinotecan (IRI) in relapsed small cell lung cancer (SCLC) patients (pts) with chemotherapy-free interval (CTFI)>30 days (d) Congress:ESMO 2024, Search all connections
Abstract Second OS interim analysis from BEAT-SC: A randomized phase III study of bevacizumab (bev) or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) Congress:ESMO 2024, Search all connections
Abstract Final overall survival analysis of JCOG1205/1206: Phase III study of irinotecan/cisplatin (IP) versus etoposide/cisplatin (EP) for completely resected high-grade neuroendocrine carcinoma (HGNEC) of the lung Congress:ESMO 2024, Search all connections
Abstract Intracranial response in patients (pts) with baseline (BL) brain metastases (BM) and extensive-stage (ES) small cell lung cancer (SCLC) treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study Congress:ESMO 2024, Search all connections
Abstract PERELI, a phase II, open label, multicenter study of pemigatinib and retifanlimab in advanced dedifferentiated liposarcoma Congress:ESMO 2024, Search all connections
Abstract Pasireotide as maintenance treatment in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor: The PAMSARC study Congress:ESMO 2024, Search all connections
Abstract Genetic predisposition in adult sarcoma patients: Beyond TP53 Congress:ESMO 2024, Search all connections
Abstract Assessing the role of denosumab in managing aneurysmal bone cysts: A scoping review Congress:ESMO 2024, Search all connections
Abstract Multi-omics of soft tissue sarcomas with complex karyotypes: Investigating genomic and transcriptomic differences between cell lines of the same subtype Congress:ESMO 2024, Search all connections
Abstract Homologous recombination pathway in sarcomas: A novel opportunity of therapy? Congress:ESMO 2024, Search all connections
Abstract Deep learning tertiary lymphoid structures detection on HES/H&E slides and association to survival outcome in sarcoma Congress:ESMO 2024, Search all connections
Abstract Clear cell sarcomas (CCS) express Gp100: A novel immune target for a bispecific T cell engager Congress:ESMO 2024, Search all connections
Abstract Molecular profiling from next-generation sequencing (NGS) reveals new potential therapeutic targets in patients with pediatric-type sarcomas Congress:ESMO 2024, Search all connections
Abstract Targeting B7H3 biomimetic nanoparticles for strengthening osteosarcoma photodynamic therapy through aggravating DNA damage Congress:ESMO 2024, Search all connections
Abstract Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas Congress:ESMO 2024, Search all connections
Abstract Immunological-molecular profiling of chondrosarcoma (ChS) Congress:ESMO 2024, Search all connections
Abstract Genomic and transcriptomic analysis of chondrosarcomas to explore new potential treatment options Congress:ESMO 2024, Search all connections
Abstract Phosphoproteomic biomarker for afatinib response stratification in advanced chordoma Congress:ESMO 2024, Search all connections
Abstract Blessed: Expanded yccess for DeltaRex-G in vivo gene therapy for sarcoma, pancreas and breast cancer (NCT04091295) and other solid malignancies (IND# 19130) Congress:ESMO 2024, Search all connections
Abstract Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior antiâ€“colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study Congress:ESMO 2024, Search all connections
Abstract Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior antiâ€“colony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study Congress:ESMO 2024, Search all connections
Abstract Desmoid tumors: Experience of a Spanish reference center Congress:ESMO 2024, Search all connections
Abstract Pegylated liposomal doxorubicin in symptomatic desmoid tumor Congress:ESMO 2024, Search all connections
Abstract Updated results of the RINGSIDE phase II trial and open-label extension of AL102 for treatment of desmoid tumors Congress:ESMO 2024, Search all connections
Abstract Second-line targeted therapy patterns and outcomes of advanced gastrointestinal stromal tumor: A prospective, multicentered real-world study Congress:ESMO 2024, Search all connections
Abstract Role of PIK3CA as a predictive biomarker in metastatic, imatinib-resistant GIST: A ct-DNA substudy of the VOYAGER trial Congress:ESMO 2024, Search all connections
Abstract Initial tumour size and residual mitotic count post-neoadjuvant imatinib linked to shorter relapse-free survival in GIST patients Congress:ESMO 2024, Search all connections
Abstract Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naÃ¯ve, advanced gastrointestinal stromal tumor (GIST) Congress:ESMO 2024, Search all connections
Abstract Clinical description and development of a prognosis score for neurofibromatosis type 1 (NF1) associated GISTs in the RECKGIST cohort: A retrospective study from the French NETSARC+ network Congress:ESMO 2024, Search all connections
Abstract Impact of adjuvant imatinib on recurrence for neurofibromatosis type 1 (NF1) associated GISTs: An analysis of the RECKGIST cohort from the French NETSARC+ network Congress:ESMO 2024, Search all connections
Abstract Long-term updated outcomes of a phase II study of ripretinib vs. sunitinib in chinese patients with advanced gastrointestinal stromal tumor Congress:ESMO 2024, Search all connections
Abstract Real-world efficacy of imatinib in patients with advanced GIST: The LRG registry Congress:ESMO 2024, Search all connections
Abstract Proceedings of the think tank for osteosarcoma medical advisory board meeting Congress:ESMO 2024, Search all connections
Abstract A phase I/II trial of gemcitabine, docetaxel, and hydroxychloroquine in advanced/metastatic osteosarcoma Congress:ESMO 2024, Search all connections
Abstract Multimodal therapy in first line treatment of very high risk Ewing sarcoma patients: Results of the French prospective multicenter COMBINAIR3 phase II trial Congress:ESMO 2024, Search all connections
Abstract Outcomes of multidisciplinary treatment of localized myxofibrosarcoma: Retrospective analysis from a reference center Congress:ESMO 2024, Search all connections
Abstract A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma Congress:ESMO 2024, Search all connections
Abstract Clinical and survival data of 336 myxoid liposarcoma patients: The Gustave Roussy experience Congress:ESMO 2024, Search all connections
Abstract Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis Congress:ESMO 2024, Search all connections
Abstract Vertebral MRI in the screening for bone metastasis in myxoid liposarcoma: Is it justified? Congress:ESMO 2024, Search all connections
Abstract A prospective, phase II study of tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult oft tissue sarcoma (TEASTS) Congress:ESMO 2024, Search all connections
Abstract Changes in global health status (GHS) in patients with advanced soft tissue sarcoma (STS) treated with first line palliative chemotherapy: Primary outcomes from the HOLISTIC study Congress:ESMO 2024, Search all connections
Abstract Real-world characterization of patients with advanced or metastatic dedifferentiated liposarcoma (DDLPS) in Japan in MASTER KEY project Congress:ESMO 2024, Search all connections
Abstract How to optimize the response with trabectedin in soft tissue sarcomas? Data from a high-volume center Congress:ESMO 2024, Search all connections
Abstract A phase II study of fruquintinib in the 1L or 2L treatment of unresectable metastatic soft tissue sarcoma Congress:ESMO 2024, Search all connections
Abstract Factors influencing awareness of patient associations in sarcoma: A multicentric cross-sectional study Congress:ESMO 2024, Search all connections
Abstract Ethically-sensitive clinical scenarios in adult patients with sarcomas: A real-world single-institution survey and a classification attempt Congress:ESMO 2024, Search all connections
Abstract Surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients failed with anthracyclines chemotherapy or monotherapy post-anlotinib progression: A multi-center, phase II trial Congress:ESMO 2024, Search all connections
Abstract Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) Congress:ESMO 2024, Search all connections
Abstract Results from the conference on challenges in sarcoma (CCS) 2024 Congress:ESMO 2024, Search all connections
Abstract A comparison of the risk prediction models sarculator and PERSARC in patients with localized soft tissue sarcoma of the extremities and trunk wall Congress:ESMO 2024, Search all connections
Abstract An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS) Congress:ESMO 2024, Search all connections
Abstract Sintilimab plus anlotinib in patients with advanced sarcomas (SINANLOSARC): A single-centre, single-arm, phase II trial Congress:ESMO 2024, Search all connections
Abstract Evaluation of nivolumab in cutaneous angiosarcoma management: The ANGIOCHECK study Congress:ESMO 2024, Search all connections
Abstract Update on gallant: A phase II study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab in previously treated sarcoma Congress:ESMO 2024, Search all connections
Abstract Primary pulmonary sarcoma: A EURACAN project Congress:ESMO 2024, Search all connections
Abstract Phase II study of the CDK2/4/6 inhibitor TQB3616 capsules in patients with dedifferentiated liposarcomas (DDLPS) Congress:ESMO 2024, Search all connections
Abstract Preliminary results of phase II study on preoperative intensity-modulated radiotherapy with concurrent PARP inhibitor for patients with non-metastatic inoperable or borderline operable extremity and trunk soft tissue sarcoma Congress:ESMO 2024, Search all connections
Abstract Update on SAINT: A phase II study using trabectedin (T) in combination with ipilimumab (I) and nivolumab (N) in previously treated soft tissue sarcoma Congress:ESMO 2024, Search all connections
Abstract Results of TNT: A phase II study using talimogene laherparepvec, nivolumab and trabectedin for advanced leiomyosarcoma and liposarcoma [NCT# 03886311] Congress:ESMO 2024, Search all connections
Abstract CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma Congress:ESMO 2024, Search all connections
Abstract Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1) Congress:ESMO 2024, Search all connections
Abstract Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma Congress:ESMO 2024, Search all connections
Abstract Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA Congress:ESMO 2024, Search all connections
Abstract A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC) Congress:ESMO 2024, Search all connections
Abstract Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13] Congress:ESMO 2024, Search all connections
Abstract Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups? Congress:ESMO 2024, Search all connections
Abstract Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study Congress:ESMO 2024, Search all connections
Abstract Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study. Congress:ESMO 2024, Search all connections
Abstract The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma Congress:ESMO 2024, Search all connections
Abstract A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma Congress:ESMO 2024, Search all connections
Abstract Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multi-center multi-country phase I/IIa expansion cohort Congress:ESMO 2024, Search all connections
Abstract Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens Congress:ESMO 2024, Search all connections
Abstract Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study Congress:ESMO 2024, Search all connections
Abstract Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study Congress:ESMO 2024, Search all connections
Abstract Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh) Congress:ESMO 2024, Search all connections
Abstract NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus Congress:ESMO 2024, Search all connections
Abstract Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial Congress:ESMO 2024, Search all connections
Abstract Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC) Congress:ESMO 2024, Search all connections
Abstract Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST) Congress:ESMO 2024, Search all connections
Abstract Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis Congress:ESMO 2024, Search all connections
Abstract A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naÃ¯ve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results Congress:ESMO 2024, Search all connections
Abstract Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC) Congress:ESMO 2024, Search all connections
Abstract CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC) Congress:ESMO 2024, Search all connections
Abstract A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma Congress:ESMO 2024, Search all connections
Abstract Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T Congress:ESMO 2024, Search all connections
Abstract The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention Congress:ESMO 2024, Search all connections
Abstract Psychosocial distress and spirituality among elderly patients with cancer in Nigeria Congress:ESMO 2024, Search all connections
Abstract Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients Congress:ESMO 2024, Search all connections
Abstract Raising the unheard voices of cancer caregivers in Asia: Comparative and sociodemographic analysis on quality of life Congress:ESMO 2024, Search all connections
Abstract A comprehensive approach to integrating family caregivers as partners in outpatient cancer care in Germany Congress:ESMO 2024, Search all connections
Abstract Insights into the daily lives and perceptions of cancer survivors: What hides beyond survival? Congress:ESMO 2024, Search all connections
Abstract Self-care confidence as a predictor of symptom burden and quality of life in people living with myeloproliferative neoplasms Congress:ESMO 2024, Search all connections
Abstract Assessment of health-related quality of life, psychosocial distress and financial toxicity among prostate cancer patients in luth: A cross-sectional survey in south-west Nigeria Congress:ESMO 2024, Search all connections
Abstract Evaluation of sleep disturbance in cancer patients: A cross-sectional study Congress:ESMO 2024, Search all connections
Abstract Factors mediating the association between adverse life experiences and pain in patients with localized breast cancer Congress:ESMO 2024, Search all connections
Abstract Self-reported cancer-related cognitive impairment (CRCI) in early breast cancer among Egyptian women: Is disease biology the key? Congress:ESMO 2024, Search all connections
Abstract Tunisian couples confronted with breast cancer Congress:ESMO 2024, Search all connections
Abstract Sexual health among men receiving chemotherapy: A double burden or a haven? Congress:ESMO 2024, Search all connections
Abstract Sexuality among Tunisian breast cancer survivors Congress:ESMO 2024, Search all connections
Abstract Impact of adjuvant hormonal therapy on sexual and global quality of life in young egyptian women with breast cancer Congress:ESMO 2024, Search all connections
Abstract Assessment of sexuality in patients with nasopharyngeal carcinoma Congress:ESMO 2024, Search all connections
Abstract Medical oncologists with imposter syndrome suffer from burnout Congress:ESMO 2024, Search all connections
Abstract Living the waiting: Feelings and experiences data from cancer patients in the waiting room Congress:ESMO 2024, Search all connections
Abstract Impact of online delivery of potentially sensitive test results on patients with breast cancer's emotional health Congress:ESMO 2024, Search all connections
Abstract Fear of cancer recurrence and its predictors in lymphoma patients and their family caregivers: A cross-sectional study Congress:ESMO 2024, Search all connections
Abstract The burden of shame and guilt: Quality of life in patients with cervical intraepithelial neoplasia (CIN) and cervical cancer â€“ A preliminary study Congress:ESMO 2024, Search all connections
Abstract Unaddressed distress in cancer patients and primary care giver: A cross-sectional comparative study at a Quaternary Government Institute Congress:ESMO 2024, Search all connections
Abstract Psychological issues and neurocognitive functioning in long-term advanced cancer survivors treated with immune checkpoint blockade Congress:ESMO 2024, Search all connections
Abstract Impact of substance use and mental health disorders on cancer care in urban underserved communities Congress:ESMO 2024, Search all connections
Abstract Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients Congress:ESMO 2024, Search all connections
Abstract Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes Congress:ESMO 2024, Search all connections
Abstract CYP11A1 inhibitor opevesostat (MK-5684) alone or in combination with other therapies for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): The phase I/II MK-5684-01A substudy Congress:ESMO 2024, Search all connections
Abstract HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa) Congress:ESMO 2024, Search all connections
Abstract SEGNO: An exploratory study of the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer Congress:ESMO 2024, Search all connections
Abstract First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Congress:ESMO 2024, Search all connections
Abstract A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer Congress:ESMO 2024, Search all connections
Abstract The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT) Congress:ESMO 2024, Search all connections
Abstract The STAMPEDE2 stereotactic ablative body radiotherapy (SABR) trial: A phase III, randomised, open-label trial in patients with newly diagnosed oligometastatic prostate cancer (PC) starting androgen deprivation therapy (ADT) Congress:ESMO 2024, Search all connections
Abstract The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT) Congress:ESMO 2024, Search all connections
Abstract Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study Congress:ESMO 2024, Search all connections
Abstract TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC) Congress:ESMO 2024, Search all connections
Abstract Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC) Congress:ESMO 2024, Search all connections
Abstract SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC) Congress:ESMO 2024, Search all connections
Abstract Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of Franceâ€™s early access program Congress:ESMO 2024, Search all connections
Abstract Fuzuloparib plus abiraterone acetate and prednisone (AA-P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase I study Congress:ESMO 2024, Search all connections
Abstract Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial Congress:ESMO 2024, Search all connections
Abstract Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI) Congress:ESMO 2024, Search all connections
Abstract Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study Congress:ESMO 2024, Search all connections
Abstract A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results Congress:ESMO 2024, Search all connections
Abstract Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients Congress:ESMO 2024, Search all connections
Abstract PSA trajectories and prediction of time to no-longer clinically benefitting in metastatic castration-resistant prostate cancer: Insights from the ProBio trial Congress:ESMO 2024, Search all connections
Abstract Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC). Congress:ESMO 2024, Search all connections
Abstract Integrated prognostic score in metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel: A CABASTY posthoc analysis Congress:ESMO 2024, Search all connections
Abstract Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects Congress:ESMO 2024, Search all connections
Abstract Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients Congress:ESMO 2024, Search all connections
Abstract Self efficacy in people with prostate cancer in the UK: A large, digital survey Congress:ESMO 2024, Search all connections
Abstract Enzalutamide (enza) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age Congress:ESMO 2024, Search all connections
Abstract Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study Congress:ESMO 2024, Search all connections
Abstract Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial Congress:ESMO 2024, Search all connections
Abstract Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients Congress:ESMO 2024, Search all connections
Abstract Does lower serum testosterone predict metastases-free survival in nmCRPC patients treated with novel antiandrogens? A post-hoc analysis of SPARTAN and ARAMIS Congress:ESMO 2024, Search all connections
Abstract Phase III study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort Congress:ESMO 2024, Search all connections
Abstract Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial Congress:ESMO 2024, Search all connections
Abstract Results from the quick efficacy seeking trial (QuEST1) arm combining BN-brachyury (BNVax) + bintrafusp alfa (BA) + nogapendekin alfa inbakicept-pmln (N-803) in castration-resistant prostate cancer (CRPC) Congress:ESMO 2024, Search all connections
Abstract A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC) Congress:ESMO 2024, Search all connections
Abstract Lutetium-177â€“prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra) Congress:ESMO 2024, Search all connections
Abstract Factors influencing clinical and biological response in patients treated with [177Lu]Lu-PSMA-617 under France's early access program Congress:ESMO 2024, Search all connections
Abstract Long survivors after androgen deprivation therapy (ADT) with or without docetaxel for metastatic castration-sensitive prostate cancer (mCSPC): Long-term follow-up of GETUG-15 Congress:ESMO 2024, Search all connections
Abstract Incidence of hematologic toxicities in the homologous recombination repair (HRR)-deficient population of the TALAPRO-2 trial and their potential association with germline vs somatic origin of HRR gene alterations Congress:ESMO 2024, Search all connections
Abstract Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study Congress:ESMO 2024, Search all connections
Abstract Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study Congress:ESMO 2024, Search all connections
Abstract Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial Congress:ESMO 2024, Search all connections
Abstract A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up Congress:ESMO 2024, Search all connections
Abstract Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy Congress:ESMO 2024, Search all connections
Abstract Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216) Congress:ESMO 2024, Search all connections
Abstract Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial Congress:ESMO 2024, Search all connections
Abstract Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304) Congress:ESMO 2024, Search all connections
Abstract Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naÃ¯ve metastatic castrate resistant prostate cancer Congress:ESMO 2024, Search all connections
Abstract Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE) Congress:ESMO 2024, Search all connections
Abstract A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) Congress:ESMO 2024, Search all connections
Abstract PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT) Congress:ESMO 2024, Search all connections
Abstract Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study Congress:ESMO 2024, Search all connections
Abstract Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC) Congress:ESMO 2024, Search all connections
Abstract Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore Congress:ESMO 2024, Search all connections
Abstract Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig Congress:ESMO 2024, Search all connections
Abstract PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer Congress:ESMO 2024, Search all connections
Abstract Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial Congress:ESMO 2024, Search all connections
Abstract Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304) Congress:ESMO 2024, Search all connections
Abstract Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591 Congress:ESMO 2024, Search all connections
Abstract Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results Congress:ESMO 2024, Search all connections
Abstract PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naÃ¯ve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW Congress:ESMO 2024, Search all connections
Abstract Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC) Congress:ESMO 2024, Search all connections
Abstract CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results Congress:ESMO 2024, Search all connections
Abstract First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naÃ¯ve prostate cancer (mHNPC) Congress:ESMO 2024, Search all connections
Abstract Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC) Congress:ESMO 2024, Search all connections
Abstract Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore Congress:ESMO 2024, Search all connections
Abstract Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study Congress:ESMO 2024, Search all connections
Abstract Cancer mortality in young population and estimated radon areas in Spain Congress:ESMO 2024, Search all connections
Abstract Factors associated with multiple general practitioner consultations before cancer diagnosis in adolescents and young adults: A cohort study in Australia Congress:ESMO 2024, Search all connections
Abstract Awareness and interest of oncology professionals in sex and gender differences in cancer risk and outcome: Analysis of an ESMO Gender Medicine Task Force survey Congress:ESMO 2024, Search all connections
Abstract Development and economic trends in new anticancer therapies licensed in the UK from 2020 to 2024 Congress:ESMO 2024, Search all connections
Abstract Prevalence and impact on survival of presentation to the emergency room of cancer patients: A retrospective study on real-life data Congress:ESMO 2024, Search all connections
Abstract Ramping up phase I trial recruitment: Defining potential barriers and disparities Congress:ESMO 2024, Search all connections
Abstract Interventions to improve Herpes Zoster (HZ) vaccination rate among cancer outpatients receiving systemic treatments: A single-center real-world experience Congress:ESMO 2024, Search all connections
Abstract As seen through Hollywoodâ€™s lens: Cancer in movies, 2010-2020 Congress:ESMO 2024, Search all connections
Abstract Current status of breast cancer: A comparative analysis between developed and developing countries Congress:ESMO 2024, Search all connections
Abstract Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023) Congress:ESMO 2024, Search all connections
Abstract Association of travel burden (TB) with colorectal cancer (CRC) outcomes in resource-limited settings (RLS) Congress:ESMO 2024, Search all connections
Abstract Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade Congress:ESMO 2024, Search all connections
Abstract Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD) Congress:ESMO 2024, Search all connections
Abstract AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC) Congress:ESMO 2024, Search all connections
Abstract Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US Congress:ESMO 2024, Search all connections
Abstract The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system Congress:ESMO 2024, Search all connections
Abstract Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs Congress:ESMO 2024, Search all connections
Abstract Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study Congress:ESMO 2024, Search all connections
Abstract Smoking and lung cancer mortality in Italian men and women: 2003-2019 Congress:ESMO 2024, Search all connections
Abstract Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain Congress:ESMO 2024, Search all connections
Abstract Medical oncology residents mentors (MORM): A target for resiliency interventions Congress:ESMO 2024, Search all connections
Abstract Global cancer statistics for adolescents and young adults: New estimates from GLOBOCAN 2022 Congress:ESMO 2024, Search all connections
Abstract Factors associated with career choice in oncology among medical students Congress:ESMO 2024, Search all connections
Abstract The reasons that motivate a change of specialties among oncology residents Congress:ESMO 2024, Search all connections
Abstract Factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in China Congress:ESMO 2024, Search all connections
Abstract Secondary delay in breast cancer diagnosis and role of rural medical practitioners: A cause and cure finding study Congress:ESMO 2024, Search all connections
Abstract Challenges in pilot lung cancer screening in Vojvodina, Serbia Congress:ESMO 2024, Search all connections
Abstract Physicians' adenoma detection rate and the risk of colorectal cancer in sequential screening programs: An observational cohort study Congress:ESMO 2024, Search all connections
Abstract Optimizing participation in lung cancer screening program: Results from the first round in ILYAD study in Lyon University Hospital Congress:ESMO 2024, Search all connections
Abstract Improving lung cancer screening selection: Hunt Lung Cancer Model (HUNT LCM) versus PLCOm2012, early results after two rounds of screening in a prospective screening pilot study in Norway (TIDL) Congress:ESMO 2024, Search all connections
Abstract Limited participation in breast cancer screening among low-SES women: A matter of engagement or of health literacy? Congress:ESMO 2024, Search all connections
Abstract Increasing the earlier detection of lung cancer: A toolbox for change Congress:ESMO 2024, Search all connections
Abstract The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia Congress:ESMO 2024, Search all connections
Abstract Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot Congress:ESMO 2024, Search all connections
Abstract Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers Congress:ESMO 2024, Search all connections
Abstract Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit Congress:ESMO 2024, Search all connections
Abstract Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population Congress:ESMO 2024, Search all connections
Abstract The use of patient experience in UK NICE decision making in oncology Congress:ESMO 2024, Search all connections
Abstract Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe Congress:ESMO 2024, Search all connections
Abstract Estimating the social value of immuno-oncology (IO) therapies in Japan Congress:ESMO 2024, Search all connections
Abstract Co payments in cancer patients: Analysis and estimating OOP Congress:ESMO 2024, Search all connections
Abstract Access to EMA approved drugs in Europe, disparities across a border Congress:ESMO 2024, Search all connections
Abstract Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan Congress:ESMO 2024, Search all connections
Abstract Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price Congress:ESMO 2024, Search all connections
Abstract Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence Congress:ESMO 2024, Search all connections
Abstract Accelerating access to innovative oncology drugs: Insights from France's early access reform Congress:ESMO 2024, Search all connections
Abstract Real-world impact of the platinum chemotherapy shortage on advanced cancer patients Congress:ESMO 2024, Search all connections
Abstract Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022) Congress:ESMO 2024, Search all connections
Abstract Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance Congress:ESMO 2024, Search all connections
Abstract Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial Congress:ESMO 2024, Search all connections
Abstract A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) Congress:ESMO 2024, Search all connections
Abstract Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2â€“positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study Congress:ESMO 2024, Search all connections
Abstract TWINPEAK phase I/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and/or pembrolizumab in gastric/GEJ-carcinomas or PDAC Congress:ESMO 2024, Search all connections
Abstract Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine and nab-paclitaxel in patients with Claudin18.2 positive locally advanced unresectable or metastaticpancreatic cancer. Congress:ESMO 2024, Search all connections
Abstract Fruquinitinib combined with nab-paclitaxel and gemcitabine (AG) as the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with liver metastases: An open-label, single-arm, single-center phase II clinical study Congress:ESMO 2024, Search all connections
Abstract TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S- 1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer Congress:ESMO 2024, Search all connections
Abstract GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611) Congress:ESMO 2024, Search all connections
Abstract Anti-PD-L1/TGF-Î²RII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine in previously untreated patients with locally advanced or metastatic pancreatic cancer: A multicenter, phase Ib/II study Congress:ESMO 2024, Search all connections
Abstract Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study Congress:ESMO 2024, Search all connections
Abstract Preliminary phase I safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients with advanced unresectable or metastatic solid tumors Congress:ESMO 2024, Search all connections
Abstract Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer Congress:ESMO 2024, Search all connections
Abstract S-1 monotherapy versus nanoliposomal irinotecan plus 5-fluorouracil/leucovorin regimen for second-line therapy of recurrent or metastatic pancreatic cancer (JON 2109-P) Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of liposomal irinotecan plus S-1 in patients with metastatic pancreatic cancer after failure of first-line gemcitabine-based chemotherapy: Result of a phase I/II study Congress:ESMO 2024, Search all connections
Abstract Real-world assessment of NALIRIFOX for advanced pancreatic ductal adenocarcinoma: An exploratory analysis Congress:ESMO 2024, Search all connections
Abstract Real-world evidence on long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan: NALLONG study Congress:ESMO 2024, Search all connections
Abstract Stereotactic radiotherapy and IMM-101 in patients with oligometastatic pancreatic cancer following FOLFIRINOX: The MEPANC trial Congress:ESMO 2024, Search all connections
Abstract Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study Congress:ESMO 2024, Search all connections
Abstract Lung-only metastatic PDAC: Another disease? Congress:ESMO 2024, Search all connections
Abstract Surgery versus chemotherapy for pulmonary oligometastasis after pancreatectomy: A multicentre observational study Congress:ESMO 2024, Search all connections
Abstract A prospective, single-center, randomized, controlled, evaluator-blinded, feasibility clinical trial for efficacy and safety of a non-tissue destructive compact focused ultrasound system with neoadjuvant FOLFIRINOX in locally advanced or borderline resectable pancreatic cancer Congress:ESMO 2024, Search all connections
Abstract Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC) Congress:ESMO 2024, Search all connections
Abstract The role of pancreaticoduodenectomy for octogenarians with pancreatic cancer Congress:ESMO 2024, Search all connections
Abstract The influence of intratumoral bacteria and peri-operative antibiotic treatment on the outcome of resected pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy Congress:ESMO 2024, Search all connections
Abstract Exploration of circulating free bacterial DNA as a biomarker for therapy response in metastatic and locally advanced pancreatic cancer patients treated with systemic chemotherapy Congress:ESMO 2024, Search all connections
Abstract Cytokines and ductal pancreatic adenocarcinoma: Exploring their relationship with prognosis and molecular subtypes Congress:ESMO 2024, Search all connections
Abstract Tumor-specific circulating cell-free DNA (ctDNA) and its clinical value in predicting response to palliative systemic treatment or survival in patients with pancreatic cancer: A systematic review and meta-analysis Congress:ESMO 2024, Search all connections
Abstract Revolutionizing clinical trials: Harnessing artificial intelligence for optimized phase III studies in pancreatic cancer Congress:ESMO 2024, Search all connections
Abstract ctDNA testing based on deep NGS predicts treatment efficacy and prognosis in advanced pancreatic cancer patients Congress:ESMO 2024, Search all connections
Abstract Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts) Congress:ESMO 2024, Search all connections
Abstract Spiritual needs in cancer patients: A cross-sectional study Congress:ESMO 2024, Search all connections
Abstract Sexual dysfunction and quality of life in rectal cancer Congress:ESMO 2024, Search all connections
Abstract Sex-specific variation in symptoms presentation: Experience of an outpatient clinic integrated model between radiotherapy and palliative care Congress:ESMO 2024, Search all connections
Abstract Caring for carers: The impact of death & dying on doctors-in-training in an Irish tertiary referral hospital Congress:ESMO 2024, Search all connections
Abstract Knowledge, attitudes, and current practices toward lung cancer palliative care management in China: A national survey Congress:ESMO 2024, Search all connections
Abstract Acute myeloid leukemia: Trends in palliative care utilization in hospitalized patients over 65 years old Congress:ESMO 2024, Search all connections
Abstract Resuscitation decisions in advanced cancer: A mixed methods study exploring survival outcomes and views of healthcare professionals Congress:ESMO 2024, Search all connections
Abstract Predictors of early mortality after hemodialysis in patients with cancer and acute kidney injury Congress:ESMO 2024, Search all connections
Abstract Impact of social isolation on the clinical outcomes in advanced NSCLC patients Congress:ESMO 2024, Search all connections
Abstract Prognostic features in NSCLC patients with ECOG-PS 2-4: A prospective cohort study Congress:ESMO 2024, Search all connections
Abstract The Italian version of the FAMCARE-P13 questionnaire: A validation study Congress:ESMO 2024, Search all connections
Abstract The role of LACE index in predicting 30-day unplanned readmission in patients receiving immunotherapy Congress:ESMO 2024, Search all connections
Abstract Palliative care of E-warm model for driver-gene-negative non-small cell lung cancer patients: A single-center randomized controlled trial Congress:ESMO 2024, Search all connections
Abstract Health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain: A cross-sectional analytical study Congress:ESMO 2024, Search all connections
Abstract Factors influencing adherence to electronic patient-reported outcomes in palliative cancer care Congress:ESMO 2024, Search all connections
Abstract Use of mobile app â€œSUPPORT+â€� to enhance community palliative care in advanced cancer patients: A feasibility study Congress:ESMO 2024, Search all connections
Abstract Telemonitoring system effectiveness for alleviating cancer pain in patients with advanced cancer Congress:ESMO 2024, Search all connections
Abstract A personalized rehabilitation pilot program for improving QOL of unresectable metastatic lung cancer patients Congress:ESMO 2024, Search all connections
Abstract Mitigating symptom clusters of patients with metastatic cancer through a remote physical exercise program (EXIO) Congress:ESMO 2024, Search all connections
Abstract Inflammatory patterns of ascites in patients with solid tumors Congress:ESMO 2024, Search all connections
Abstract Prospective observational study to assess the prophylactic effect of topical diclofenac in preventing the development of hand foot syndrome in patients with colorectal and gastric cancer on capecitabine therapy Congress:ESMO 2024, Search all connections
Abstract Percutaneous transhepatic biliary drainage (PTBD) for palliation of jaundice in patients of unresectable/disseminated carcinoma gall bladder with hilar block: Is it a worthwhile enterprise? Congress:ESMO 2024, Search all connections
Abstract A case-control study of drug-eluting microspheres and blank microspheres in bronchial artery embolization for hemoptysis in non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer Congress:ESMO 2024, Search all connections
Abstract Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study Congress:ESMO 2024, Search all connections
Abstract Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management Congress:ESMO 2024, Search all connections
Abstract Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced G/GEJ cancer: A phase Ib/II clinical trial (FUNCTION) Congress:ESMO 2024, Search all connections
Abstract A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ) Congress:ESMO 2024, Search all connections
Abstract Neoadjuvant SOX combined with cadonilimab (AK104) for PD-L1 negative upper GC/GEJC patients Congress:ESMO 2024, Search all connections
Abstract Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group â€“ The IKF-057/ PRESTO trial Congress:ESMO 2024, Search all connections
Abstract MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physicianâ€™s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA) Congress:ESMO 2024, Search all connections
Abstract Phase I trial of intraperitoneal infusion of GAIA-102 of NK-Like CD3-negative cells for gastric/pancreatic cancer Congress:ESMO 2024, Search all connections
Abstract Development of an efficacy prediction model for concurrent chemoradiotherapy in esophageal squamous cell carcinoma using deep learning and multimodal data integration Congress:ESMO 2024, Search all connections
Abstract cGAS-driven inflammation in chromosomally unstable oesophagogastric adenocarcinoma Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer (GC/EGJC): Data update from a phase II single-arm study Congress:ESMO 2024, Search all connections
Abstract Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy Congress:ESMO 2024, Search all connections
Abstract Chemo-radiation alone associated with higher risk of death compared to chemo-radiation plus surgery in esophageal squamous cell carcinoma Congress:ESMO 2024, Search all connections
Abstract The presence of liver metastases is associated with systemic immune suppression in gastroesophageal cancer Congress:ESMO 2024, Search all connections
Abstract A pilot study of hypoxia as a potential resistance mechanism to PD-1 checkpoint blockade therapy in neoadjuvant treatment of esophageal squamous cell carcinoma (HYPERION) Congress:ESMO 2024, Search all connections
Abstract Analysis of MET gene alterations in cfDNA samples from a phase II study of savolitinib in patients (pts) with MET-amplified gastroesophageal junction adenocarcinomas or gastric cancer (GEJ/GC) Congress:ESMO 2024, Search all connections
Abstract Association between effectiveness of treatment with curative intent and outcomes of first-line systemic therapy in metachronous metastatic esophagogastric cancer Congress:ESMO 2024, Search all connections
Abstract Long-term management and outcomes in gastroesophageal cancer in Norway Congress:ESMO 2024, Search all connections
Abstract Impact of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) on staging and treatment in patients with gastric cancer Congress:ESMO 2024, Search all connections
Abstract Tumor immune microenvironment subtypes of esophageal squamous cell carcinoma and their strong ability to predict the efficacy of neoadjuvant immunotherapy Congress:ESMO 2024, Search all connections
Abstract First in human phase I/II trial of claudin 18.2 ADC RC118 in patients with advanced gastric/gastroesophageal junction cancer Congress:ESMO 2024, Search all connections
Abstract Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastroesophageal junction cancer: A prospective, single-arm, phase II clinical trial Congress:ESMO 2024, Search all connections
Abstract An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001) Congress:ESMO 2024, Search all connections
Abstract A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC) Congress:ESMO 2024, Search all connections
Abstract Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial Congress:ESMO 2024, Search all connections
Abstract Neoadjuvant and adjuvant pembrolizumab (pembro) + chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Patient-reported outcomes (PROs) from the phase III KEYNOTE-585 study Congress:ESMO 2024, Search all connections
Abstract Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial Congress:ESMO 2024, Search all connections
Abstract Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305 Congress:ESMO 2024, Search all connections
Abstract IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts Congress:ESMO 2024, Search all connections
Abstract Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of cadonilimab combined albumin-paclitaxel, cisplatin and fluorouracil (APF) in neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): Results from the CAPITAL trial Congress:ESMO 2024, Search all connections
Abstract Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma Congress:ESMO 2024, Search all connections
Abstract Nature trumps nurture: Squamous cell carcinoma remains the leading cause of esophageal cancer in Asian-Americans Congress:ESMO 2024, Search all connections
Abstract Association between fruquintinib-induced hypertension and clinical outcomes from FRUTIGA, a phase III study of fruquintinib plus paclitaxel in previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma Congress:ESMO 2024, Search all connections
Abstract Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy Congress:ESMO 2024, Search all connections
Abstract Clinical application of a machine learning-based pathomics signature for predicting lymph node metastasis in early gastric cancer Congress:ESMO 2024, Search all connections
Abstract Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase II trial. Congress:ESMO 2024, Search all connections
Abstract ABBV-400, a c-Met proteinâ€“targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study Congress:ESMO 2024, Search all connections
Abstract First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW Congress:ESMO 2024, Search all connections
Abstract Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up Congress:ESMO 2024, Search all connections
Abstract Better overall survival of male versus female patients with advanced gastric adenocarcinoma Congress:ESMO 2024, Search all connections
Abstract Immunomodulatory effects and improved survival of PG2 plus preoperative chemoradiotherapy in patients with locally advanced esophageal cancer Congress:ESMO 2024, Search all connections
Abstract Impact of subsequent anti-tumor therapies in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma receiving fruquintinib (F) plus paclitaxel (PTX) or placebo plus PTX in FRUTIGA study Congress:ESMO 2024, Search all connections
Abstract A phase I/II study of FG-M108 plus capecitabine and oxaliplatin (CAPOX) as first-line (1L) treatment for patients with CLDN18.2+/HER2- advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma Congress:ESMO 2024, Search all connections
Abstract Safety of laparoscopic D2 distal gastrectomy following neoadjuvant chemotherapy for locally advanced gastric cancer patients: A prospective multicenter trial (CLASS-03a) Congress:ESMO 2024, Search all connections
Abstract Assessing pathological complete response to neoadjuvant chemotherapy combined with immunotherapy in esophageal squamous cell carcinoma: A deep learning approach with voxel-level radiomics Congress:ESMO 2024, Search all connections
Abstract Impact of menadione supplementation in the treatment of patients with metastatic gastric cancer: A randomized phase II clinical trial Congress:ESMO 2024, Search all connections
Abstract Differences in esophageal cancer incidence and survival by race/ethnicity: A SEER analysis Congress:ESMO 2024, Search all connections
Abstract Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: An international cohort study Congress:ESMO 2024, Search all connections
Abstract Predicting overall survival and prognostic indicator genes in esophagogastric cancer patients using machine learning and bioinformatics analysis Congress:ESMO 2024, Search all connections
Abstract BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of KN026 in combination with chemotherapy in patients (pts) with unresectable or metastatic HER2 positive gastric or gastroesophageal cancers (GC/GEJC) after first-line treatment with a trastuzumab-containing regimen Congress:ESMO 2024, Search all connections
Abstract Maintenance capecitabine plus ramucirumab after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma (OGA): Final analysis from the PLATFORM trial Congress:ESMO 2024, Search all connections
Abstract Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial Congress:ESMO 2024, Search all connections
Abstract First-line rilvegostomig (rilve) + chemotherapy (CTx) in patients (pts) with HER2-negative (HER2â€“) locally advanced unresectable or metastatic gastric cancers: First report of GEMINI-Gastric sub study 2 Congress:ESMO 2024, Search all connections
Abstract Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer Congress:ESMO 2024, Search all connections
Abstract Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) Congress:ESMO 2024, Search all connections
Abstract Osemitamab (TST001) plus nivolumab and CAPOX as the first-line therapy for the patients with advanced G/GEJ cancer (TranStar102) Congress:ESMO 2024, Search all connections
Abstract Tumor microenvironment B-cell abundance and survival in resectable gastric cancer: A translational analysis from the CLASSIC trial Congress:ESMO 2024, Search all connections
Abstract Comparative efficacy and safety of tislelizumab versus anti-PD-1 treatments in second-line esophageal squamous cell carcinoma: Simulated treatment comparisons Congress:ESMO 2024, Search all connections
Abstract First-line tislelizumab combined with bevacizumab and CAPOX for metastatic gastroesophageal adenocarcinoma (mGEA) with PD-L1 CPS<5: Updated results of a phase II, prospective, single-arm study Congress:ESMO 2024, Search all connections
Abstract Real-world data on the use of nivolumab plus chemotherapy for patients with metastatic GC/GEJC/EAC: A Canadian perspective Congress:ESMO 2024, Search all connections
Abstract Iparomlimab and tuvonralimab (QL1706) with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: An open-label phase II study Congress:ESMO 2024, Search all connections
Abstract Multi-modal deep-learning model for real-time prediction of recurrence in early-stage esophageal cancer: A multi-modal approach Congress:ESMO 2024, Search all connections
Abstract Intestinal microbiota as a biological marker for pre-neoplastic lesion in gastric cancer in Amazonas, Brazil Congress:ESMO 2024, Search all connections
Abstract AI-powered immune phenotype predicts favorable outcomes of nivolumab (niv) plus chemotherapy (chemo) in advanced fgastric cancer (AGC): A multi-center real-world data analysis Congress:ESMO 2024, Search all connections
Abstract Efficacy of fruquintinib plus paclitaxel (F+PTX) in patients (pts) with prior immunotherapy (prior-IO): Subgroup analysis from FRUTIGA study Congress:ESMO 2024, Search all connections
Abstract Advancing esophageal cancer radiotherapy: AS-NeSt's 3D predictive proficiency for personalized dose distribution Congress:ESMO 2024, Search all connections
Abstract DVDMS (Sinoporphyrin sodium)-mediated photodynamic therapy (PDT) vs treatment of physicianâ€™s choice in patients with advanced esophageal cancer (EC): Preliminary results of DYNA-Esophagus03, a randomized, open-labeled, multicenter phase IIIb study Congress:ESMO 2024, Search all connections
Abstract Pan-immune-inflammation value predicts the survival of patients with esophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: A pooled-analysis of two phase II trials Congress:ESMO 2024, Search all connections
Abstract Interim response evaluation from a phase II study of capecitabine, oxaliplatin, and anti-PD-1 in dMMR esophagogastric cancer (AuspiCiOus trial) Congress:ESMO 2024, Search all connections
Abstract Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for esophageal squamous cell carcinoma (EC-CRT-001 phase II trial) Congress:ESMO 2024, Search all connections
Abstract Predictive role of circulating cytokines in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with anti-PD1 inhibitor: Pooled analyses of two phase II clinical trials Congress:ESMO 2024, Search all connections
Abstract A phase II study of tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: Long-term follow-up outcomes of TD-NICE Congress:ESMO 2024, Search all connections
Abstract Phase III, double-blind study of cannabis sativa extract in pain management and quality of life in patients with metastatic lung cancer: Protocol of a study (IPElife trial) Congress:ESMO 2024, Search all connections
Abstract Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC) Congress:ESMO 2024, Search all connections
Abstract Phase III trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy Congress:ESMO 2024, Search all connections
Abstract Osimertinib combined with dalpiciclib in EGFR-mutant, CDK4/6 pathway-altered, advanced NSCLC patients with acquired resistance to third-generation EGFR-TKIs: A phase II, prospective, multicenter, single-arm clinical trial Congress:ESMO 2024, Search all connections
Abstract A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02) Congress:ESMO 2024, Search all connections
Abstract KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation Congress:ESMO 2024, Search all connections
Abstract A phase II/III study to evaluate the optimal dose, safety, and efficacy of livmoniplimab (Livmo) in combination with budigalimab (Budi) plus chemotherapy (CT) vs pembrolizumab (Pembro) plus CT in untreated metastatic non-small cell lung cancer (mNSCLC) Congress:ESMO 2024, Search all connections
Abstract Phase III study of pembrolizumab plus MK-1084 vs pembrolizumab plus placebo as first-line treatment for metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 tumour proportion score (TPS) â‰¥50%: MK-1084-004 Congress:ESMO 2024, Search all connections
Abstract TACTC-2 trial: Efficacy of pembrolizumab Â± chemotherapy first-line therapy in advanced non-small cell lung cancer patients with PD-L1 expression â‰¥50% adjusting in accordance with CtDNA Congress:ESMO 2024, Search all connections
Abstract Clinical characteristics and treatment outcomes of patients with thoracic SMARCA4-deficient tumour Congress:ESMO 2024, Search all connections
Abstract Safety and effectiveness of immune checkpoint inhibitor therapy in patients with lung cancer and pre-existing autoimmune disease Congress:ESMO 2024, Search all connections
Abstract Molecular testing in patients with advanced NSCLC from 2016-23 (Prospective German Registry CRISP, AIO-TRK-0315) Congress:ESMO 2024, Search all connections
Abstract Real-world data, tolerability and clinical outcomes in patients with advanced NSCLC treated with sotorasib in the UK Congress:ESMO 2024, Search all connections
Abstract Prognostic value of EGFR A859S alteration in advanced NSCLC patients treated with third-generation EGFR-TKI Congress:ESMO 2024, Search all connections
Abstract Uncovering resistance mechanisms and vulnerabilities of KEAP1 mutated lung adenocarcinoma Congress:ESMO 2024, Search all connections
Abstract Efficacy of cemiplimab as monotherapy or in combination with chemotherapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC) Congress:ESMO 2024, Search all connections
Abstract Distribution of actionable genetic variants in different sample types of Chinese NSCLC: A large real-world data based study Congress:ESMO 2024, Search all connections
Abstract Vebreltinib efficacy and safety in NSCLC patients with METex14 skipping mutations Congress:ESMO 2024, Search all connections
Abstract Comparison between standard dose 75mg/m2 and fixed dose at 50mg of cisplatin in the treatment of non-small cell lung cancer patients in term of response rate and toxicity profile Congress:ESMO 2024, Search all connections
Abstract PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial Congress:ESMO 2024, Search all connections
Abstract c-Met protein overexpression and telisotuzumab vedotin efficacy by biopsy age, type, and region in the LUMINOSITY phase II study Congress:ESMO 2024, Search all connections
Abstract Improvements in stage IV non-small cell lung cancer survival differ by race in the US Congress:ESMO 2024, Search all connections
Abstract Association of anatomic proximity of brain parenchymal metastasis to the CSF space and upfront stereotactic radiosurgery to subsequent leptomeningeal metastasis development in brain metastatic NSCLC Congress:ESMO 2024, Search all connections
Abstract Early detection of disease progression in NSCLC patients undergoing immunotherapy through ctDNA analysis Congress:ESMO 2024, Search all connections
Abstract Sequential ctDNA profiling in patients with advanced non-small cell lung cancer: An interim analysis of the COPE randomized study Congress:ESMO 2024, Search all connections
Abstract Analysis of evolution of patient reported side effects during treatment for advanced NSCLC Congress:ESMO 2024, Search all connections
Abstract Measuring PFS in clinical trials and observational studies of patients with NSCLC: A scoping review Congress:ESMO 2024, Search all connections
Abstract Advanced non-small cell lung carcinoma in the era of immunotherapy: Survival and the risk of multiple primary malignancies Congress:ESMO 2024, Search all connections
Abstract An anti-EpCAM x CD3 bispecific antibody, M701, for the treatment of malignant pleural effusion in NSCLC patients: Intermediate results of a prospective multicenter phase Ib trial Congress:ESMO 2024, Search all connections
Abstract Survival of de novo metastatic non-small cell lung cancer according to biomarker status in Denmark and Norway: A register-based cohort study Congress:ESMO 2024, Search all connections
Abstract Trilaciclib combined with intraventricular injection chemotherapy in the treatment of advanced NSCLC with leptomeningeal metastasis: A prospective, single-arm, phase II clinical trial Congress:ESMO 2024, Search all connections
Abstract Correlation between depth of response at 6 months and survival in patients (pts) with metastatic non-small cell lung carcinoma (mNSCLC): SPORE trial Congress:ESMO 2024, Search all connections
Abstract Sex disparities in patient and tumour characteristics, and overall survival in advanced non-small cell lung cancer (NSCLC) within the precision oncology era: A Danish nationwide observational study Congress:ESMO 2024, Search all connections
Abstract Natural Language Processing (NLP) as promising artificial intelligence (AI) tool to improve patients (pts) enrollment in clinical trials (CT): Analysis in real-world conditions on a lung cancer cohort Congress:ESMO 2024, Search all connections
Abstract Does cancer care differ for older adults with lung cancer living with and without Alzheimer disease and related dementias (ADRD)? Congress:ESMO 2024, Search all connections
Abstract Federated analysis of overall survival (OS) by location of metastases (mets) in patients (pts) with metastatic NSCLC (mNSCLC) from the Digital Oncology Network for Europe (DigiONE) Congress:ESMO 2024, Search all connections
Abstract An AI-derived tool to pre-screen lung cancer candidates for clinical trials Congress:ESMO 2024, Search all connections
Abstract Evaluation of imaging-based prognostication (IPRO) for advanced non-small cell lung cancer (aNSCLC) using deep learning applied to computed tomography (CT) Congress:ESMO 2024, Search all connections
Abstract The Stereotactic Radiosurgery-Brain Prognostic Index (SRS-BPI): A novel prognostic index for lung cancer patients with brain metastases eligible for SRS Congress:ESMO 2024, Search all connections
Abstract Combining immunotherapy and hybrid dose-fraction radiotherapy (Hybrid-RT) for driver-negative metastatic non-small cell lung cancer patients (NSCLC): A single-arm multi-center phase II study (NCT05348668) Congress:ESMO 2024, Search all connections
Abstract Lack of Abscopal effect and radiotherapy-induced lymphocyte depletion in advanced non-small cell lung cancer (NSCLC) patients treated with atezolizumab and radiotherapy Congress:ESMO 2024, Search all connections
Abstract Plinabulin/docetaxel versus docetaxel in survival benefits of 2L/3L EGFR wild-type NSCLC after platinum regimens (DUBLIN-3): A randomized phase III trial Congress:ESMO 2024, Search all connections
Abstract Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study Congress:ESMO 2024, Search all connections
Abstract Transcriptomic inflammatory profiling of non-small cell lung cancer: Insights from a 7-gene expression analysis Congress:ESMO 2024, Search all connections
Abstract Real-world (RW) treatment patterns and survival outcomes by PD-L1 expression in stage IV non-squamous (nsq) non-small cell lung cancer (NSCLC): A retrospective analysis of the UK National Cancer Registry Database (NCRAS) Congress:ESMO 2024, Search all connections
Abstract Retrospective audit to determine the effect of antibiotic therapy on immune checkpoint inhibitor efficacy in stage IV NSCLC Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of docetaxel in combination with nintedanib or ramucirumab following immune checkpoint-Inhibitor treatment in patients with non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy Congress:ESMO 2024, Search all connections
Abstract Heme-oxygenase-1 (HO-1) as a potential biomarker for ICIs in patients with advanced lung cancer Congress:ESMO 2024, Search all connections
Abstract Phase I/II trial shows promising efficacy of nadunolimab in combination with platinum doublet as second-line therapy in patients with NSCLC Congress:ESMO 2024, Search all connections
Abstract A prospective study on cliniciansâ€™ attitudes and survival outcomes for patients with NSCLC and poor performance status in the immunotherapy era: PICASO study (GOIRC-04-2020) Congress:ESMO 2024, Search all connections
Abstract First-line (1L) nivolumab (N) + ipilimumab (I) with 2 cycles of platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): Results from an interim analysis of the German non-interventional study (NIS) FINN Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of immune checkpoint inhibitor rechallenge in advanced lung cancer: A multicenter, real-world study Congress:ESMO 2024, Search all connections
Abstract A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC) Congress:ESMO 2024, Search all connections
Abstract Surufatinib plus toripalimab combined with pemetrexed (A), and platinum (P) in patients (pts) with advanced non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results of a single-center, phase II trial Congress:ESMO 2024, Search all connections
Abstract Plasma proteomics indicated predictive biomarkers for immuno-chemotherapy in stage IIIB-IV non-small cell lung cancer without EGFR/ALK alterations Congress:ESMO 2024, Search all connections
Abstract Adding histology-driven chemotherapy (ChT) to overcome primary resistance to first-line immunotherapy (ICI) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) with PD-L1 â‰¥50% Congress:ESMO 2024, Search all connections
Abstract The efficacy of pembrolizumab vs nivolumab plus ipilimumab in metastatic NSCLC in relation to PD-L1 and TMB status Congress:ESMO 2024, Search all connections
Abstract Exploring the role of the gut microbiome on the efficacy of ipilimumab and nivolumab in advanced non-small cell lung cancer: A prospective observational study Congress:ESMO 2024, Search all connections
Abstract A phase II study of docetaxel (D), ramucirumab (R), and pembrolizumab (P) for pts with metastatic or recurrent non-small cell lung cancer (NSCLC) who progressed on platinum-doublet and PD-1/PD-L1 blockade Congress:ESMO 2024, Search all connections
Abstract Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC Congress:ESMO 2024, Search all connections
Abstract TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC) Congress:ESMO 2024, Search all connections
Abstract Clinical outcomes, toxic effect, and changes of immune microenvironment of drug-eluting beads bronchial artery chemoembolization (DEB-BACE) combined with immunotherapy in the treatment of elder patients with non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract The relationship between nivolumab pharmacokinetics and cancer cachexia biomarkers in patients with metastatic non-small cell lung cancer (NSCLC) Congress:ESMO 2024, Search all connections
Abstract PET/CT-guided immune checkpoint blocker treatment discontinuation vs treatment continuation in lung cancer long-term responders: A National Network Genomic Medicine Lung Cancer Germany (nNGM) analysis Congress:ESMO 2024, Search all connections
Abstract Prognostic value of circulating nucleosomes during treatment with or without immunotherapy in non-small lung cancer (NSCLC): Results from the NUCLEO-lung study Congress:ESMO 2024, Search all connections
Abstract Effects of immune checkpoint inhibitors for EGFR-wild/ALK-negative NSCLC patients with untreated brain metastases Congress:ESMO 2024, Search all connections
Abstract Efficacy, innovativeness, clinical trials, endpoints, and price of drugs with FDA approval for non-small cell lung cancer (NSCLC) Congress:ESMO 2024, Search all connections
Abstract Phase II study of pembrolizumab (pemb) plus plinabulin (plin) and docetaxel (doc) for patients (pts) with metastatic NSCLC after failure on first-line immune checkpoint inhibitor alone or combination therapy: Initial efficacy and safety results on Immune Re-sensitization Congress:ESMO 2024, Search all connections
Abstract Fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naÃ¯ve EGFR- and ALK-negative non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results Congress:ESMO 2024, Search all connections
Abstract Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients Congress:ESMO 2024, Search all connections
Abstract Lung immune prognostic index (LIPI) as a guide for addition of chemotherapy in immunotherapy in elderly patients (Pts) with non-small cell lung cancer (NSCLC): NEJ057 Congress:ESMO 2024, Search all connections
Abstract Clinical and genomic characteristics of advanced non-small cell lung cancer (aNSCLC) patients (pts) with long-term response to first-line (1L) immunotherapy: A real-world study Congress:ESMO 2024, Search all connections
Abstract TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial Congress:ESMO 2024, Search all connections
Abstract Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial Congress:ESMO 2024, Search all connections
Abstract RATIONALE-307 long-term outcomes: First-line tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone for advanced squamous (sq) NSCLC Congress:ESMO 2024, Search all connections
Abstract A phase II trial of autologous cytokine-induced killer (CIK) therapy plus toripalimab with or without chemotherapy as first-line treatment in advance NSCLC Congress:ESMO 2024, Search all connections
Abstract Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy Congress:ESMO 2024, Search all connections
Abstract Impact of concomitant co-medications on survival with first-line pembrolizumab in 43,000 French patients with advanced NSCLC Congress:ESMO 2024, Search all connections
Abstract Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC) Congress:ESMO 2024, Search all connections
Abstract Real-world immunotherapy (IO) rechallenge outcomes with nivolumab (NIV) in advanced non-small cell lung cancer (aNSCLC) in France: LIST study interim results Congress:ESMO 2024, Search all connections
Abstract BC3195, a novel ADC targeting CDH3: Preliminary results of a first-in human phase I study in patients with advanced solid malignancies Congress:ESMO 2024, Search all connections
Abstract Patient-reported outcomes (PROs) from the phase III EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel (doc) in metastatic non-small cell lung cancer (mNSCLC) Congress:ESMO 2024, Search all connections
Abstract Patient-reported outcomes (PROs) in the LUMINOSITY trial: Evaluating telisotuzumab vedotin (Teliso-V) in patients (Pts) with c-Met protein overexpressing (OE), EGFR wildtype, non-squamous non-small cell lung cancer (NSQ NSCLC) Congress:ESMO 2024, Search all connections
Abstract Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01 Congress:ESMO 2024, Search all connections
Abstract Phase II, open-label study of frontline tusamitamab ravtansine with pembrolizumab Â± chemotherapy in advanced non-squamous non-small cell lung cancer: Updated results from CARMEN-LC05 trial Congress:ESMO 2024, Search all connections
Abstract SHR-A1921: A trophoblast cell-surface antigen 2 (TROP-2) targeted antibody-drug conjugate (ADC) for the treatment of advanced NSCLC Congress:ESMO 2024, Search all connections
Abstract A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A Congress:ESMO 2024, Search all connections
Abstract Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations Congress:ESMO 2024, Search all connections
Abstract Clinical characteristics and therapeutic sequences of KRAS G12C advanced non-small cell lung cancer (aNSCLC) patients (pts) treated by sotorasib in the French post-marketing authorization early access (post-MA EA) Congress:ESMO 2024, Search all connections
Abstract Trametinib plus anlotinib in non-G12C KRAS-mutant non-small cell lung cancer: A single-center, open-label, single-cohort study Congress:ESMO 2024, Search all connections
Abstract Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials Congress:ESMO 2024, Search all connections
Abstract Investigator-initiated study of crizotinib in patients with MET activated advanced stage non-small cell lung cancer: A Canadian experience Congress:ESMO 2024, Search all connections
Abstract METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence Congress:ESMO 2024, Search all connections
Abstract METÃ—MET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study Congress:ESMO 2024, Search all connections
Abstract BRAF-mutant metastatic non-small cell lung cancer: Real-world data from the Italian biomarker ATLAS database Congress:ESMO 2024, Search all connections
Abstract Treatment sequences in BRAF-V600-mutant non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy Congress:ESMO 2024, Search all connections
Abstract First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract Epidemiological and genomic features of patients (pts) with advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with HER2/ERBB2 mutations within and outside the tyrosine kinase domain (TKD) Congress:ESMO 2024, Search all connections
Abstract A phase II study of pyrotinib combined with apatinib in first-line treatment of advanced non-small cell lung cancer patients with primary HER-2 mutations/amplification Congress:ESMO 2024, Search all connections
Abstract A phase II study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification Congress:ESMO 2024, Search all connections
Abstract EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naÃ¯ve to or following prior SRI Congress:ESMO 2024, Search all connections
Abstract Non-adenocarcinoma histology in patients with RET+ lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry Congress:ESMO 2024, Search all connections
Abstract Mechanisms of resistance to selpercatinib in RET activated NSCLC and MTC from the LIBRETTO-001 trial Congress:ESMO 2024, Search all connections
Abstract A national real-world analysis of ROS1+ metastatic non-small cell lung cancer patients management (explore ALK, cohort 2, GFPC 03-2019) Congress:ESMO 2024, Search all connections
Abstract Real-world treatment and overall survival (OS) in patients (pts) with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in England between 2014 and 2023 Congress:ESMO 2024, Search all connections
Abstract Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC Congress:ESMO 2024, Search all connections
Abstract Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC) Congress:ESMO 2024, Search all connections
Abstract Clinical impact and landscape of heterogeneous ALK resistance mutations (muts) after comprehensive genomic profiling (CGP) Congress:ESMO 2024, Search all connections
Abstract Predictive value of weight and BSA in assessing toxicity during ALK-TKIs in non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract Explore-ALK (GFPC 03-2019): A real-world prospective, multicenter study of advanced ALK rearranged non-small cell lung cancer patients Congress:ESMO 2024, Search all connections
Abstract Deep learning prediction of response to advanced-generation ALK inhibitors (aALKi) in ALK-rearranged advanced NSCLC (aNSCLC) patients using digital pathology Congress:ESMO 2024, Search all connections
Abstract Clinical utility of liquid biopsy for non-small cell lung cancer patients with ALK fusion variants treated with brigatinib Congress:ESMO 2024, Search all connections
Abstract Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database Congress:ESMO 2024, Search all connections
Abstract Activity of brigatinib based on genomic alterations detected on ctDNA at baseline and at progression in ALK inhibitor-naÃ¯ve advanced ALK+ NSCLC from the ALTA-1L trial Congress:ESMO 2024, Search all connections
Abstract Impact of common germline variants on the toxicity profile and pharmacokinetics of alectinib Congress:ESMO 2024, Search all connections
Abstract Effects of semaglutide on the exposure of alectinib in patients with NSCLC Congress:ESMO 2024, Search all connections
Abstract First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study Congress:ESMO 2024, Search all connections
Abstract Update of the INSPIRE study: Iruplinalkib versus crizotinib in ALK TKI-naÃ¯ve locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC) Congress:ESMO 2024, Search all connections
Abstract Optimising targeted therapy in NSCLC: A comprehensive analysis of oncogenic fusion mutations and co-mutation landscapes Congress:ESMO 2024, Search all connections
Abstract EXcellenT (exercise in extended oncogene addicted lung cancer in active treatment) trial: Preliminary results on impact of physical activity (PA) on emotional, metabolic and immune status Congress:ESMO 2024, Search all connections
Abstract Osimertinib versus first/second generation tyrosine kinase inhibitors as first-line therapy for metastatic EGFR-mutated non-small cell lung carcinoma: Overall survival using real-world data from TriNetX platform Congress:ESMO 2024, Search all connections
Abstract Risk factors for osimertinib-induced interstitial lung disease in patients with metastatic or recurrent non-small cell lung cancer harboring epidermal growth factor receptor mutations Congress:ESMO 2024, Search all connections
Abstract Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) Congress:ESMO 2024, Search all connections
Abstract Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC Congress:ESMO 2024, Search all connections
Abstract Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial Congress:ESMO 2024, Search all connections
Abstract Preventing infusion-related reactions with intravenous amivantamab: Updated results from SKIPPirr, a phase II study Congress:ESMO 2024, Search all connections
Abstract Concordances assessment between MET-positive circulating tumour cells and disease progression in patients with EGFR mutated NSCLC Congress:ESMO 2024, Search all connections
Abstract Sequential afatinib (AFA) to osimertinib (OSI) in EGFR-mutant NSCLC: Primary analysis of Gio-Tag Japan, a multicenter prospective observational study Congress:ESMO 2024, Search all connections
Abstract Interim analysis from the multicenter ROSE study: Radiation during osimertinib treatment safety and efficacy cohort Congress:ESMO 2024, Search all connections
Abstract A promising MET-EGFR bispecific nanobody-drug conjugate therapy for multiple solid tumours Congress:ESMO 2024, Search all connections
Abstract Real-world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need Congress:ESMO 2024, Search all connections
Abstract Biomarker analysis of plasma samples in YAMATO study: A randomized phase II trial comparing switching treatment of osimertinib following 8 months of afatinib (A) and osimertinib alone (B) in untreated advanced NSCLC patients with common EGFR mutation (TORG1939/WJOG12919L) Congress:ESMO 2024, Search all connections
Abstract Combined molecular analysis of circulating tumour DNA and tumour tissue to identify osimertinib resistance Congress:ESMO 2024, Search all connections
Abstract Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutations Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal study Congress:ESMO 2024, Search all connections
Abstract Stage III non-small cell lung cancer (NSCLC) in France, characteristics treatments and survival results of French real-world data Congress:ESMO 2024, Search all connections
Abstract Retrospective evaluation of inflammatory biomarkers in patients affected by unresectable stage III NSCLC: Final results of NEUTRALITY trial Congress:ESMO 2024, Search all connections
Abstract Impact of systemic treatment on cardiac events following chemoradiotherapy in stage III lung cancer patients Congress:ESMO 2024, Search all connections
Abstract Health-related quality of life (HRQoL) at diagnosis for unresectable stage III NSCLC: Results from the French nationwide prospective study OBSTINATE (GFPC 06-2019) Congress:ESMO 2024, Search all connections
Abstract Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: LAURA China cohort analysis Congress:ESMO 2024, Search all connections
Abstract Radiotherapy (RT) patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients (pts) with Stage III unresectable non-small cell lung cancer (UR-NSCLC) treated with durvalumab (D) after chemoradiotherapy (CRT) Congress:ESMO 2024, Search all connections
Abstract PIT-3: A multicenter phase II trial of erlotinib induction followed by surgery in stage IIIA (N2) EGFR mutated non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy vs. neoadjuvant chemotherapy in lung cancer treatment: A mixed method meta-analysis based on global randomized controlled trials Congress:ESMO 2024, Search all connections
Abstract Association of tumor-draining lymph node metastatic patterns and neoadjuvant immunochemotherapy effectiveness in resectable non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract NEO-PIONEER: Neoadjuvant hypofractionated radiotherapy plus tislelizumab with anlotinib followed by adjuvant tislelizumab with anlotinib in patients with resectable non-small cell lung cancer (NSCLC): A phase II trial in progress Congress:ESMO 2024, Search all connections
Abstract Combining immunotherapy with Trop2 ADc in early stage non-small cell lung cancer (CITADEL) Congress:ESMO 2024, Search all connections
Abstract Association of LRRC15 protein expression with 5-year survival in lung adenocarcinoma patients Congress:ESMO 2024, Search all connections
Abstract ctDNA-Lung-Detect: Profiling of non-shedding ctDNA early stage resected non-small cell lung cancers Congress:ESMO 2024, Search all connections
Abstract Pathologic response as a surrogate endpoint for event-free survival in neo-adjuvant immunotherapy trials of resectable non-small cell lung cancer: A subgroup analysis Congress:ESMO 2024, Search all connections
Abstract Stage migration in resectable NSCLC Congress:ESMO 2024, Search all connections
Abstract Genomic scarring score as a criterion for PARP inhibitor administration in early-stage NSCLC Congress:ESMO 2024, Search all connections
Abstract Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI+CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI) Congress:ESMO 2024, Search all connections
Abstract Clinical characteristics and real-world treatment patterns in stage I-III resectable NSCLC: THASSOS-INTL study Congress:ESMO 2024, Search all connections
Abstract Association between early endpoints and survival outcomes in neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC): A multi-country retrospective study Congress:ESMO 2024, Search all connections
Abstract Precision patient selection for postoperative therapy in resectable NSCLC: A comprehensive postoperative-risk model incorporating genetic and histological features Congress:ESMO 2024, Search all connections
Abstract Association between air pollution and frequency of driver mutation among a Hispanic population with lung cancer Congress:ESMO 2024, Search all connections
Abstract Update on the analysis of operability parameter changes in neoadjuvant treatment with chemotherapy and anti-PD-1/PD-L1 Congress:ESMO 2024, Search all connections
Abstract Predictive value of circulating tumor DNA (ctDNA) before and shortly after curative treatment in early stage non-small cell lung cancer (NSCLC), and exploration of (pre-)analytical factors Congress:ESMO 2024, Search all connections
Abstract Perioperative serplulimab and chemotherapy in patients with resectable squamous non-small cell lung cancer: An open-label, single-arm, phase II trial Congress:ESMO 2024, Search all connections
Abstract Evaluation of safety and feasibility of adjuvant chemotherapy in elderly patients with primary non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract Sex specific efficacy and safety outcomes in operable stage III non-small cell lung cancer (NSCLC): Pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14 Congress:ESMO 2024, Search all connections
Abstract Predicting pathological complete response to neoadjuvant chemoimmunotherapy in resected NSCLC with radiomic signatures Congress:ESMO 2024, Search all connections
Abstract Stereotactic ablative radiotherapy in combination with nivolumab for early stage operable non-small cell lung cancer: A phase II study Congress:ESMO 2024, Search all connections
Abstract A phase III randomized trial investigating preventive effects of perioperative landiolol, a selective beta1 blocker, on the reduction of recurrence of completely resected NSCLC Congress:ESMO 2024, Search all connections
Abstract Integrating artificial intelligence (AI)-based lymphocytic infiltration assessment in early stage NSCLC: A sub-study of the TNM-I trial Congress:ESMO 2024, Search all connections
Abstract FALCONS, a non-interventional retrospective study in resected NSCLC patients using the EPITHOR database, first analysis Congress:ESMO 2024, Search all connections
Abstract B cell infiltration and memory TOX+ CD8+ T cells in stage I-II non-small cell lung cancer (NSCLC) predict response to neoadjuvant pembrolizumab: A phase I study Congress:ESMO 2024, Search all connections
Abstract Adjuvant pembrolizumab therapy for completely resected stage I NSCLC with micropapillary or solid histological subtype Congress:ESMO 2024, Search all connections
Abstract United Kingdom (UK) real world study of adjuvant osimertinib in resected EGFR mutated lung cancer Congress:ESMO 2024, Search all connections
Abstract Imaging AI prognosis of early stage lung cancer using CT radiomics Congress:ESMO 2024, Search all connections
Abstract Neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS vs. neoadjuvant placebo (PBO) plus CT with adjuvant PBO in resectable non-small cell lung cancer (NSCLC): patient-reported outcomes (PRO) in the RATIONALE-315 trial Congress:ESMO 2024, Search all connections
Abstract IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 TCâ‰¥50% NSCLC who were disease-free at 5 years (5yDF) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo) Congress:ESMO 2024, Search all connections
Abstract IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC) Congress:ESMO 2024, Search all connections
Abstract Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study Congress:ESMO 2024, Search all connections
Abstract A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy Congress:ESMO 2024, Search all connections
Abstract Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project Congress:ESMO 2024, Search all connections
Abstract Analytical evaluation of whole genome sequencing for acute myeloid leukemia Congress:ESMO 2024, Search all connections
Abstract A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC Congress:ESMO 2024, Search all connections
Abstract Novel deep learning model and validation of whole slide images in lung cancer diagnosis Congress:ESMO 2024, Search all connections
Abstract Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes Congress:ESMO 2024, Search all connections
Abstract Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing Congress:ESMO 2024, Search all connections
Abstract Analytical validation of an NGS panel-based ecDNA detection device for use as a clinical trial assay for the POTENTIATE clinical study of the novel CHK1 inhibitor, BBI-355 Congress:ESMO 2024, Search all connections
Abstract Ex vivo basket study reports patient-specific sensitivity to carboplatin versus cisplatin in lung, ovarian and bladder cancer Congress:ESMO 2024, Search all connections
Abstract Organoid growth-based oncological sensitivity test (OncoSensi) for predicting adjuvant therapy outcomes in ovarian cancer patients Congress:ESMO 2024, Search all connections
Abstract Whole-body magnetic resonance imaging (WB-MRI) screening in Li Fraumeni syndrome for early cancer diagnosis: The SIGNIFIED project Congress:ESMO 2024, Search all connections
Abstract Development of a novel artificial intelligence (AI) algorithm to detect pulmonary nodules on chest radiography Congress:ESMO 2024, Search all connections
Abstract Ethical lung cancer screening selection? Comparison of the European 4 Congress:ESMO 2024, Search all connections
Abstract Optimizing lung cancer screening: Independent verification of an AI/ML computer-aided detection and characterization software as medical device Congress:ESMO 2024, Search all connections
Abstract Efficient lung cancer stage prediction and outcome informatics with Bayesian deep learning and MCMC method Congress:ESMO 2024, Search all connections
Abstract Circulating tumor DNA from the tumor-draining pulmonary vein as a biomarker in resected non-small cell lung cancer Congress:ESMO 2024, Search all connections
Abstract Cancer genome interpreter: A data-driven tool for tumor mutation interpretation Congress:ESMO 2024, Search all connections
Abstract Modeled economic and clinical impact of a multi-cancer early detection (MCED) test in a population with hereditary cancer syndromes Congress:ESMO 2024, Search all connections
Abstract Molecular diagnosis of lung cancer via ctDNA and ctRNA detection on bronchoscopic fluid specimens from 31 patients: A retrospective analysis Congress:ESMO 2024, Search all connections
Abstract SmartCS-LPLLM: Enhancing early cancer detection through ctDNA methylation analysis leveraging large language models Congress:ESMO 2024, Search all connections
Abstract Clinical applications of a novel blood-based fragmentomics assay for lung cancer detection Congress:ESMO 2024, Search all connections
Abstract Early real-world experience with positive multi-cancer early detection (MCED) test cases and negative initial diagnostic work-up Congress:ESMO 2024, Search all connections
Abstract Impact of multicancer early detection (MCED) test on participant-reported outcomes (PRO) and behavioral intentions by cancer risk Congress:ESMO 2024, Search all connections
Abstract Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform Congress:ESMO 2024, Search all connections
Abstract Diagnostic target product profiles for cancer: A demand signaling tool to stimulate innovation in early cancer diagnosis Congress:ESMO 2024, Search all connections
Abstract An integrated metabolomics-based platform for early-stage detection of multiple cancers Congress:ESMO 2024, Search all connections
Abstract WomEC: a novel diagnostic test for the detection of endometrial cancer in uterine fluids Congress:ESMO 2024, Search all connections
Abstract EGFR evaluation in non-small cell lung cancer: An artificial intelligence approach to pre-molecular analysis Congress:ESMO 2024, Search all connections
Abstract FRESH: The Gustave Roussy program to facilitate access to liquid biopsy for precision oncology in France Congress:ESMO 2024, Search all connections
Abstract Potential utility of ctDNA to detect false positive PET/CT in the evaluation of lymphoma response Congress:ESMO 2024, Search all connections
Abstract Universal circulating tumor DNA quantification using deep learning Congress:ESMO 2024, Search all connections
Abstract FLAMINGO: Accurate cancer detection from ultra-low-pass whole genome sequencing of cell-free DNA Congress:ESMO 2024, Search all connections
Abstract Combining mass spectrometry with quantitative continuous scoring to unlock the full quantitative potential of immunohistochemistry Congress:ESMO 2024, Search all connections
Abstract Convergent and divergent determinants of heterogeneity, biomarkers, and plasticity in thoracic and prostate neuroendocrine tumors Congress:ESMO 2024, Search all connections
Abstract Clustering of patients with lung neuroendocrine neoplasms using machine learning and its association with survival: A population based study from the U.S. SEER database Congress:ESMO 2024, Search all connections
Abstract Overall survival (OS) and progression-free survival (PFS) in patients with advanced, non-resectable, progressive rectal NET treated with 90Y DOTA-TATE, 177Lu DOTA-TATE and mix of both as systemic radioligand therapy: Real-world data Congress:ESMO 2024, Search all connections
Abstract Outcomes of local and systemic treatment in primary hepatic neuroendocrine neoplasms (PHNEN) Congress:ESMO 2024, Search all connections
Abstract 21-day modified CAPTEM protocol is effective and safe for patients with advanced well-differentiated grade 1/2 pancreatic neuroendocrine tumors Congress:ESMO 2024, Search all connections
Abstract The significance and indications for lymphadenectomy in pancreatic neuroendocrine neoplasms Congress:ESMO 2024, Search all connections
Abstract The influence of neoadjuvant radiotherapy on surgical management and prognostic outcomes in locally advanced rectal neuroendocrine carcinoma Congress:ESMO 2024, Search all connections
Abstract Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT) Congress:ESMO 2024, Search all connections
Abstract Transcriptomic analysis of gastroenteropancreatic neuroendocrine tumours with carcinoid syndrome Congress:ESMO 2024, Search all connections
Abstract Progression-free survival ratio and the implications for treatment sequencing in neuroendocrine neoplasms Congress:ESMO 2024, Search all connections
Abstract An Italian multicenter phase II trial of metronomic temozolomide in unfit patients with advanced neuroendocrine neoplasms: Interim analysis of the MeTe study Congress:ESMO 2024, Search all connections
Abstract Molecular characterization of extra-pulmonary mixed adeno-neuroendocrine carcinomas: The NIRVANA substudy Congress:ESMO 2024, Search all connections
Abstract A novel nomogram for predicting overall survival of small intestinal neuroendocrine tumors treated with PRRT Congress:ESMO 2024, Search all connections
Abstract Retreatment with peptide receptor radionuclide therapy (PRRT) in patients (p) with neuroendocrine tumors (NET): Spanish clinical experience from SEPTRALU national registry Congress:ESMO 2024, Search all connections
Abstract The efficacy of lower doses of everolimus in patients with advanced neuroendocrine tumors Congress:ESMO 2024, Search all connections
Abstract Updated results of surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: A prospective, randomized, controlled trial Congress:ESMO 2024, Search all connections
Abstract Prospective multinational evaluation of alkylating-induced hypermutation in neuroendocrine neoplasms (NEN): Clinical and molecular profiles associated with response to immune checkpoint inhibitors (CPI) Congress:ESMO 2024, Search all connections
Abstract Preclinical characterization of MC339: A novel radiotherapeutic agent for DLL3 expressing cancers Congress:ESMO 2024, Search all connections
Abstract Correlation of biochemical secretion and imaging parameters on [18F]-SiTATE-PET/CT in pheochromocytoma and paraganglioma Congress:ESMO 2024, Search all connections
Abstract Biochemical and radiological efficacy of systmic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma/pheochromocytoma (PPGL) sporadic and hereditary Congress:ESMO 2024, Search all connections
Abstract Search for biomarkers to personalize treatment with streptozotocin plus 5-fluorouracil or everolimus in patients with advanced pancreatic neuroendocrine tumors: The randomized phase III SEQTOR trial (GETNE-1206) Congress:ESMO 2024, Search all connections
Abstract Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab Congress:ESMO 2024, Search all connections
Abstract IDE196 (darovasertib) in combination with crizotinib versus investigatorâ€™s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma Congress:ESMO 2024, Search all connections
Abstract A prospective study of patients with immune checkpoint inhibitor-induced hepatitis: Management outcome and association with liver injury subtype, immune infiltration, and clinical parameters Congress:ESMO 2024, Search all connections
Abstract Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors Congress:ESMO 2024, Search all connections
Abstract Cosibelimab in advanced cutaneous squamous cell carcinoma (CSCC): Longer-term efficacy and safety results from pivotal study Congress:ESMO 2024, Search all connections
Abstract Multi-modal and longitudinal characterization of the tumor and immune microenvironment of Merkel cell carcinoma Congress:ESMO 2024, Search all connections
Abstract Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for â‰¥1 or â‰¥2 years in JAVELIN Merkel 200 Congress:ESMO 2024, Search all connections
Abstract Only early adjuvant radiotherapy, particularly of the tumor bed rather than the lymph node region, improves prognosis in Merkel cell carcinoma: Results from the prospective German MCC registry Congress:ESMO 2024, Search all connections
Abstract Regorafenib in Caucasian patients with pretreated advanced KIT-mutant melanoma: A dual center case series Congress:ESMO 2024, Search all connections
Abstract A phase II study of pembrolizumab combination with temozolomide as 1L treatment for Chinese metastatic acral melanoma patients Congress:ESMO 2024, Search all connections
Abstract Phase II trial on nivolumab plus radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial Congress:ESMO 2024, Search all connections
Abstract Clinical outcomes from a tebentafusp UK expanded access program in patients with metastatic uveal melanoma (mUM) Congress:ESMO 2024, Search all connections
Abstract Preliminary results of first-in-human study of 225-Actinium MTI-201 (225Ac-MTI-201) in metastatic uveal melanoma Congress:ESMO 2024, Search all connections
Abstract Subgroup analysis of FOCUS phase III trial efficacy results Congress:ESMO 2024, Search all connections
Abstract A phase II study of nivolumab/relatlimab in metastatic uveal melanoma Congress:ESMO 2024, Search all connections
Abstract Accuracy of PET-CT to assess extent of nodal disease in clinical stage III melanoma Congress:ESMO 2024, Search all connections
Abstract Adjuvant treatment of patients with stage III melanoma: 4-year follow-up time of multicenter real-world study Congress:ESMO 2024, Search all connections
Abstract Melanoma incidence and mortality decline in younger adults in Sweden: Start of a shift in the upgoing trend? Congress:ESMO 2024, Search all connections
Abstract The role of imaging during follow-up after radical surgery of stage IIb-c and III cutaneous malignant melanoma: Survival results from an interim analysis of a randomized prospective multicenter study (TRIM) Congress:ESMO 2024, Search all connections
Abstract Artificial Intelligence to predict BRAF mutational status from whole slide images in melanoma Congress:ESMO 2024, Search all connections
Abstract Tumoral and peripheral immunophenotype of patients with stage II/III melanoma undergoing adjuvant immunotherapy following tumor resection Congress:ESMO 2024, Search all connections
Abstract Genomic and transcriptomic predictors of resistance to anti-PD1 monotherapy in patients with advanced melanoma Congress:ESMO 2024, Search all connections
Abstract Immunological alterations during neoadjuvant BRAF/MEK inhibition in patients with prior unresectable regionally advanced melanoma: Translational analysis from the REDUCTOR trial Congress:ESMO 2024, Search all connections
Abstract Intratumoral microbiota is associated with prognosis in Chinese patients with skin melanoma Congress:ESMO 2024, Search all connections
Abstract Application of the Scottish inflammatory prognostic score to the south-east Scotland cancer network real-world melanoma cohort Congress:ESMO 2024, Search all connections
Abstract Multiomics clustering of patients with cutaneous melanoma to reveal survival trends based on tumor immune evasion features Congress:ESMO 2024, Search all connections
Abstract Deciphering unresectable in-transit metastasis in melanoma: Multi-modal and longitudinal insights Congress:ESMO 2024, Search all connections
Abstract A machine learning model based on computed tomography radiomics to predict prognosis in subjects with stage IV melanoma Congress:ESMO 2024, Search all connections
Abstract Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition Congress:ESMO 2024, Search all connections
Abstract Genomic and transcriptomic analysis of Japanese melanoma reveals candidate biomarkers for immune checkpoint inhibitor responders Congress:ESMO 2024, Search all connections
Abstract Follow-up brain imaging in patients with melanoma brain metastasis and immune checkpoint inhibitors Congress:ESMO 2024, Search all connections
Abstract Association of clinical features with long-term survival in patients with melanoma who responded to distinct checkpoint inhibitors Congress:ESMO 2024, Search all connections
Abstract Impact of quantitative imaging of all disease on the prognostic value of 18F-FDG PET/CT in patients treated with immunotherapy for metastatic melanoma Congress:ESMO 2024, Search all connections
Abstract Characteristics and quality of life of nine-year survivors from 312 patients with metastatic melanoma treated with pembrolizumab Congress:ESMO 2024, Search all connections
Abstract NivoLag-when: International real-world study of combination immunotherapy sequences in melanoma Congress:ESMO 2024, Search all connections
Abstract Predicting the outcomes of advanced cutaneous melanoma cases following discontinuation of immune checkpoint inhibition Congress:ESMO 2024, Search all connections
Abstract Early time-point 18F-FDG-PET/CT at week four (W4) as a prognostic biomarker of survival in metastatic melanoma (mM) patients (pts) on immunotherapy Congress:ESMO 2024, Search all connections
Abstract Real-world efficacy of relatlimab and nivolumab in advanced or resectable melanoma Congress:ESMO 2024, Search all connections
Abstract Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma Congress:ESMO 2024, Search all connections
Abstract Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study) Congress:ESMO 2024, Search all connections
Abstract Anti-PD1 + low-dose anti-CTLA4 immunotherapy pathological response rate in patients with stage III resectable melanoma: Phase III NEOMIMAJOR trial interim analysis Congress:ESMO 2024, Search all connections
Abstract COMBI-EU: Adverse event management of adjuvant dabrafenib plus trametinib (D+T) in patients with BRAF V600-mutant melanoma Congress:ESMO 2024, Search all connections
Abstract Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial Congress:ESMO 2024, Search all connections
Abstract Long-term follow-up of advanced melanoma (unresectable/metastatic Congress:ESMO 2024, Search all connections
Abstract Camrelizumab plus apatinib in patients with advanced mucosal melanoma: A 3-year survival update with biomarker analysis Congress:ESMO 2024, Search all connections
Abstract Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial Congress:ESMO 2024, Search all connections
Abstract NeoRisk: Neoadjuvant immunotherapy (NeoIT) recurrence risk assessment tool Congress:ESMO 2024, Search all connections
Abstract Preliminary biomarker analysis in the phase III PIVOTAL study: Evidence for the mechanism of action of daromun in melanoma Congress:ESMO 2024, Search all connections
Abstract Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047 Congress:ESMO 2024, Search all connections
Abstract Neoadjuvant cemiplimab for stage IIâ€“IV cutaneous squamous cell carcinoma (CSCC): 2-year follow-up and biomarker analyses Congress:ESMO 2024, Search all connections
Abstract High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma Congress:ESMO 2024, Search all connections
Abstract Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma Congress:ESMO 2024, Search all connections
Abstract Molecular profiling and matched targeted therapy for patients with advanced melanoma: Results from part I of the MatchMEL study Congress:ESMO 2024, Search all connections
Abstract Phase II study of niraparib in patients with advanced melanoma with homologous recombination pathway gene mutations Congress:ESMO 2024, Search all connections
Abstract Intratumoral (IT) administration of autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with the immunologic adjuvant AS01B plus ipilimumab (IPI) and IV nivolumab (NIVO) in patients with refractory advanced melanoma: A phase Ib clinical trial Congress:ESMO 2024, Search all connections
Abstract Adoptive cell therapy with TCR gene-engineered T cells directed against MAGE-C2-positive melanoma: An ongoing phase I trial Congress:ESMO 2024, Search all connections
Abstract Phase II study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma Congress:ESMO 2024, Search all connections
Abstract KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma Congress:ESMO 2024, Search all connections
Abstract A phase I trial of ATG-101, an investigational PD-L1Ã—4-1BB bispecific antibody, in patients with advanced solid tumors and mature B cell non-Hodgkin lymphomas: PROBE-CN Congress:ESMO 2024, Search all connections
Abstract A phase I study of GIGA-564, a minimally blocking anti-CTLA-4 monoclonal antibody Congress:ESMO 2024, Search all connections
Abstract A phase I/IIa first in-human phase I study of BI 1910, a monoclonal antibody agonistic to TNFR2, as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I/II dose escalation/expansion trial to evaluate safety and preliminary efficacy of DuoBody-EpCAMÃ—4-1BB (BNT314/GEN1059) alone or in combination with an immune checkpoint inhibitor in patients with malignant solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors Congress:ESMO 2024, Search all connections
Abstract A phase Ia/Ib dose-escalation/expansion study of NPX887 in subjects with solid tumor malignancies known to express HHLA2/B7-H7 Congress:ESMO 2024, Search all connections
Abstract A phase I/IIa dose escalation and expansion study of 23ME-01473, an anti-ULBP6/2/5 antibody, for patients with advanced solid malignancies Congress:ESMO 2024, Search all connections
Abstract Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate) Congress:ESMO 2024, Search all connections
Abstract Steroid and antibiotic treatment are associated with diverse immunotherapy efficacy: A pooled analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC trials of the German AIO study group Congress:ESMO 2024, Search all connections
Abstract Potential effects of olanzapine: Enhancing the immune response to PD-1/PD-L1 inhibitors Congress:ESMO 2024, Search all connections
Abstract Dose dependent detrimental effect of baseline pantoprazole on clinical outcomes from first-line chemo-ICI regimens in patients with advanced stage NSCLC Congress:ESMO 2024, Search all connections
Abstract Optimizing infusion rates of monoclonal antibodies to save time for oncology day care and patients Congress:ESMO 2024, Search all connections
Abstract Influence of infusion timing on the outcomes of immunotherapy in a multi-tumor cohort Congress:ESMO 2024, Search all connections
Abstract Effect of the immunological circadian rhythm on the treatment of locally advanced non-small cell lung cancer treated with consolidation immunotherapy Congress:ESMO 2024, Search all connections
Abstract Assessing differential informative censoring in control and experimental arm in trials testing immunotherapy in metastatic cancers: A systematic review Congress:ESMO 2024, Search all connections
Abstract Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: A metrology informatics analysis based on machine learning Congress:ESMO 2024, Search all connections
Abstract Association between tumor longevity and immune-checkpoint inhibitor outcomes: A retrospective study in head and neck, lung, renal/urothelial cancers Congress:ESMO 2024, Search all connections
Abstract Hyperprogressive disease during immune checkpoint inhibitor: A cloudy phenomenon with real consequences Congress:ESMO 2024, Search all connections
Abstract Blinded independent central review versus local investigator assessment of progression-free survival in randomized controlled trials of immunotherapy in advanced cancers: A systematic review and meta-analysis Congress:ESMO 2024, Search all connections
Abstract Real-world usage and adverse events (AE) of immune checkpoint inhibitors (ICI): A large-scale, automated, GDPR-compliant analysis of hospital records Congress:ESMO 2024, Search all connections
Abstract Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancers Congress:ESMO 2024, Search all connections
Abstract CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatment Congress:ESMO 2024, Search all connections
Abstract The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based study Congress:ESMO 2024, Search all connections
Abstract Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signatures Congress:ESMO 2024, Search all connections
Abstract Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitors Congress:ESMO 2024, Search all connections
Abstract Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAE Congress:ESMO 2024, Search all connections
Abstract Cytokine release syndrome in patients treated with bispecific T cell engagers and bispecific monoclonal antibodies at The Christie: A retrospective study Congress:ESMO 2024, Search all connections
Abstract Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter study Congress:ESMO 2024, Search all connections
Abstract Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritis Congress:ESMO 2024, Search all connections
Abstract Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapy Congress:ESMO 2024, Search all connections
Abstract The association of human leukocyte antigen variants in immune-related toxicity and efficacy in Chinese lung cancer patients treated with immune checkpoint inhibitors Congress:ESMO 2024, Search all connections
Abstract UniTope & TraCR: Universal tagging and tracking system for TCR-T cells integrated directly in the TCR constant region Congress:ESMO 2024, Search all connections
Abstract Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations Congress:ESMO 2024, Search all connections
Abstract Rapid, single-step monitoring of circulating monoclonal antibodies using an aptamer-based electrochemical sensing platform Congress:ESMO 2024, Search all connections
Abstract ODI-2001, a personalized combinatorial immunotherapy shows antitumoral activity across different syngeneic mice tumor models, including 4T1 Congress:ESMO 2024, Search all connections
Abstract Chemotherapy remodels the tumor immune microenvironment to increase the pCR rate of anti-PD-1 neoadjuvant therapy in MSS/pMMR locally advanced colon cancer: A prospective clinical trial and translational study Congress:ESMO 2024, Search all connections
Abstract Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy Congress:ESMO 2024, Search all connections
Abstract Interactions of immune checkpoint blockade and regulatory T cells Congress:ESMO 2024, Search all connections
Abstract Activating strong anti-tumor immunity with PTPN2/PTPN1 inhibitor: AC484 Congress:ESMO 2024, Search all connections
Abstract Large-scale cellular profiling of 1283 cancer patients reveals a NK cell-mediated immunosuppressive tumor microenvironment in immunotherapy resistance Congress:ESMO 2024, Search all connections
Abstract A new IL-6 inducing mechanism in cancer with new therapeutic possibilities Congress:ESMO 2024, Search all connections
Abstract Preclinical development of genetically modified tumor-infiltrating lymphocytes using biopsy samples from liver cancer patients Congress:ESMO 2024, Search all connections
Abstract Anti-tumor efficacy and safety of conditionally activated armored CAR-T cells against gastrointestinal tumors Congress:ESMO 2024, Search all connections
Abstract Tumor-infiltrating lymphocytes with inducible membrane-tethered IL-12 cultured in optimized media exhibits superior anti-tumor activity Congress:ESMO 2024, Search all connections
Abstract Survival rates in high-risk neuroblastoma patients undergoing anti-GD2 immunotherapy: A single arm meta-analysis and systemic review Congress:ESMO 2024, Search all connections
Abstract Preclinical development of TCR-modified T cell therapies against mutated KRAS Congress:ESMO 2024, Search all connections
Abstract A phase I study of personalized KSX01-TCRT therapy for advanced solid tumor and its mechanisms Congress:ESMO 2024, Search all connections
Abstract First results for intravenous (IV) VSV-GP (BI 1831169) in patients (pts) with advanced solid tumors from the 1456-0001 study Congress:ESMO 2024, Search all connections
Abstract Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers Congress:ESMO 2024, Search all connections
Abstract Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancer Congress:ESMO 2024, Search all connections
Abstract A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) Congress:ESMO 2024, Search all connections
Abstract Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTAC Congress:ESMO 2024, Search all connections
Abstract Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01 Congress:ESMO 2024, Search all connections
Abstract Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustion Congress:ESMO 2024, Search all connections
Abstract Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer Congress:ESMO 2024, Search all connections
Abstract Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC) Congress:ESMO 2024, Search all connections
Abstract Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumours Congress:ESMO 2024, Search all connections
Abstract The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumors Congress:ESMO 2024, Search all connections
Abstract Phase Ib trial results of safety, pharmacokinetics and pharmacodynamics of TU2218, TGFÎ²-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract A phase I study of rivoceranib combined with nivolumab in patients with unresectable or metastatic cancer Congress:ESMO 2024, Search all connections
Abstract Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors Congress:ESMO 2024, Search all connections
Abstract Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Phase I dose-escalation study of HBM1020: A novel anti-B7H7 antibody in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study Congress:ESMO 2024, Search all connections
Abstract Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI) Congress:ESMO 2024, Search all connections
Abstract Phase I/II trial of ASP1570, a novel diacylglycerol kinase Î¶ inhibitor, in patients with advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970) Congress:ESMO 2024, Search all connections
Abstract A phase Ia study of the myeloid-derived suppressor cell modulator HF1K16 in refractory and metastatic cancer patients: Preliminary efficacy and safety Congress:ESMO 2024, Search all connections
Abstract First-in-human dose escalation trial of fourth generation chimeric antigen receptor (CAR) T cell therapy (EU307) in patients with glypican-3 (GPC3) positive hepatocellular carcinoma (HCC) Congress:ESMO 2024, Search all connections
Abstract Fostrox (fostroxacitabine bralpamide) plus lenvatinib in patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) progressed on immunotherapy combinations: Results from a multi-center phase Ib/IIa study Congress:ESMO 2024, Search all connections
Abstract Analysis of antidrug antibodies (ADA) to camrelizumab in CARES-310: The pivotal phase III study of camrelizumab + rivoceranib in unresectable hepatocellular carcinoma (uHCC) Congress:ESMO 2024, Search all connections
Abstract Regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: Interim results from the multicenter real-world study Congress:ESMO 2024, Search all connections
Abstract Updated safety and efficacy of ABSK-011 in advanced hepatocellular carcinoma (aHCC) with FGF19 overexpression from a phase I study Congress:ESMO 2024, Search all connections
Abstract HILL: The efficacy and safety of hepatic arterial infusion chemotherapy with FOLFOX regimen combine lenvatinib and durvalumab in unresectable hepatocellular carcinoma: A prospective, phase II, single-armed, clinical trial Congress:ESMO 2024, Search all connections
Abstract Tyrosine kinase inhibitors vs anti-VEGF antibody, combined with anti-PD-1 inhibitors and TACE in the conversion therapy for hepatocellular carcinoma: A retrospective multicenter real-world study Congress:ESMO 2024, Search all connections
Abstract Hepatic artery infusion chemotherapy (HAIC) plus sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC) in patients with Child-Pugh B liver function: A prospective study Congress:ESMO 2024, Search all connections
Abstract Initial results from the phase II randomized trial comparing TACE with irinotecan and mitomycin C to doxorubicin in intermediate stage HCC (IRITACE trial) Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety analysis of transarterial chemoembolization combined donafenib with or without immune checkpoint inhibitors in for unresectable hepatocellular carcinoma (HCC): A prospective, single-arm, single center, phase â…¡ clinical study Congress:ESMO 2024, Search all connections
Abstract Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: A multicenter cohort study Congress:ESMO 2024, Search all connections
Abstract Tislelizumab plus donafenib combined with transarterial chemoembolization in patients with resected high-risk hepatocellular carcinoma (TIDE): A prospective, single-arm, phase II trial Congress:ESMO 2024, Search all connections
Abstract Lenvatinib plus drug-eluting bead transarterial chemoembolization with or without hepatic arterial infusion chemotherapy for hepatocellular carcinoma (> 7 cm) with portal vein tumor thrombosis: A retrospective multicenter cohort study Congress:ESMO 2024, Search all connections
Abstract Surufatinib combined with anti-PD-1/PD-L1 antibody in the second-line or monotherapy in third-line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study Congress:ESMO 2024, Search all connections
Abstract Atezolizumab plus bevacizumab or lenvatinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: Overall survival using real-world data from TrinetX platform Congress:ESMO 2024, Search all connections